Protocol: J1A-MC-KDAD(b)
Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With 
Moderately to Severely Active Rheumatoid Arthritis
[STUDY_ID_REMOVED]
Approval Date: 11-Dec-2020
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 1 A -M C -K D A D( b) 
1Title P a ge 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of 
Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al 
i n v e sti g ati o n of L Y 3 4 6 2 8 1 7 , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d C o m p a n y or it s 
s u b si di ari e s. 
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a a n d/ or c o m m er ci all y c o nfi d e n ti al 
i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e.  Eli Lill y a n d C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y 
p u bli c r el e a s e.  I n t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) E x e m pti o n 4 a n d m a y n ot b e 
r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s .
Pr ot oc ol Title: A P hase 2 St u d y  t o E val uate t he Efficac y  a n d Safet y of  L Y 3 4 6 2 8 1 7 i n 
Parti ci p a nts wi t h  M o deratel y t o Se verel y Act i ve R he u m at oi d Art hri tis 
Pr ot oc ol N u m ber: J 1 A -M C -K D A D 
A me n d me nt N u m ber: ( b) 
C o m p o u n d :L Y 3 4 6 2 8 1 7 
St u d y P h ase: P hase 2
S h ort Title: A P hase 2 St u d y  t o E val uate t he Efficac y  a n d Safet y of  L Y 3 4 6 2 8 1 7 i n P arti ci pa nts 
wi t h  M o deratel y  t o Se verel y  A ct i ve R he u mat oi d Art hrit is 
Acr o n y m :K D A D 
S p o ns or N a me: El i Lill y  a n d C o m pa n y 
Le g al Re gistere d A d dress: I n dia na p o lis, I n dia na ,U S A 4 6 2 8 5 
Re g ul at or y A ge nc y I de ntifier N u m ber(s) 
I N D: 1 5 0 7 1 0 
E u dra C T n u m ber: 2 0 2 0 ‐ 0 0 2 6 7 3‐ 1 0 
A p pr o v al D ate: Pr ot oc ol A me n d me nt ( b) El ectr o nicall y Si g ne d a n d A p pr o ve d b y Lill y o n date 
pr o vi de d bel o w. 
A p pr o v al D at e: 1 1- D e c- 2 0 2 0 G M T 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
KDAD Amendment (a) 21-Sep -2020
Original Protocol 05-Aug -2020
Amendment [b] 
This amendment occurred before any study  parti cipant was consented or dosed at any  study  site 
in Europe.
Overall Rationale for the Amendment:
The purpose of this protocol amendment i s to cl arify  study  procedures and stati stical 
considerations in response to European regulatory  agency  feedback.
Section # and Name Description of Change Brief Rationale
Secti on 6.3 .Measures to Minimize Bias: 
Randomization and Blinding
Secti on7.1.2. Criteria for Permanent 
Discontinuati on of  Study  Intervent ion
Secti on 8.2.6. Tuberculosis Testing and 
Mon itoringRemoved medical monitoring 
wordingClarificat ion 
Secti on 7.1.1. Cri teria for Tem porary  
Interrupti on (Wi thholding) of Study  
Intervention
Secti on 7.1.1.1. Infection -related Cri teria 
for Tem porary  Withhol ding of Study  
Intervention 
Secti on 7.2.1. Discont inuat ion of 
Inadvertent ly Enrolled Participants Modified medical mo nitoring 
wordingClarificat ion
Secti on9.2.Sample Size De terminat ion DAS28 -CRP change 
from baseline explained 
MMRM analysis 
inform ation addedClarificat ion
Secti on 9.4.1 .General Considerat ions Clarified adjustments for 
multiplicit y Clarificat ion
Secti on 9.5 .Interim Analyses Provi ded addi tional clarificat ion 
on interim analysisClarificat ion
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
4Table of Contents
1. Protocol Summary ...................................................................................................... 7
1.1. Synopsis ....................................................................................................................... 7
1.2. Schema ....................................................................................................................... 10
1.3. Schedule of Act ivities (SoA) ...................................................................................... 11
2. Introduction .............................................................................................................. 18
2.1. Study  Rati onale .......................................................................................................... 18
2.2. Background ................................................................................................................ 18
2.3. Benefit/Risk Assessment ............................................................................................ 20
3. Objectives and Endpoints ......................................................................................... 21
4. Study Design ............................................................................................................. 23
4.1. Overall Design ............................................................................................................ 23
4.2. Scientific Rationale for Study  Design ......................................................................... 23
4.3. Justification for Dose .................................................................................................. 24
4.4. End of Study  Definit ion.............................................................................................. 25
5. Study Population ...................................................................................................... 26
5.1. Inclusio n Cri teria........................................................................................................ 26
5.2. Exclusio n Cri teria....................................................................................................... 28
5.3. Lifes tyle Considerat ions............................................................................................. 31
5.4. Screen Failures ........................................................................................................... 31
6. Study Intervention .................................................................................................... 32
6.1. Study  Intervent ion(s) Administered ............................................................................ 32
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 33
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 33
6.4. Study  Intervent ion Compliance ................................................................................... 34
6.5. Concomitant Therapy .................................................................................................34
6.5.1. Permi tted Rheum atoid Arthri tis Conco mitant Therapy ................................................ 34
6.5.2. Prohibited Conco mitant Therapy ................................................................................ 35
6.5.3. Standard of Care Therapy  after Week 14 .................................................................... 35
6.6. Dose Modificat ion...................................................................................................... 36
6.7. Intervention after the End of the Study ........................................................................ 36
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 37
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 37
7.1.1. Criteria for Tem porary  Interrupti on (Wi thhol ding) of Study  
Intervention ................................................................................................................ 37
7.1.2. Criteria for Perm anent Discont inuat ion of Study  Intervent ion..................................... 38
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 39
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Participants ............................................... 40
7.3. Lost to Follow up ....................................................................................................... 40
8. Study Assessments and Procedures ......................................................................... 41
8.1. Efficacy Assessments .................................................................................................41
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
58.1.1. Disease Act ivity Score –High-Sensi tivity C-React ive Protein 
(DAS28 -hsCRP) ......................................................................................................... 41
8.1.2. Disease Act ivity Score –Ery throcyte Sedimentati on Rate 
(DAS28 -ESR) ............................................................................................................. 41
8.1.3. American Co llege of Rheumatology Criteria (ACR20, ACR50, 
and ACR70) ............................................................................................................... 42
8.1.4. Tender Joint Count and Swollen Jo int Coun t.............................................................. 42
8.1.5. Physician’s Global Assessment of Disease Activit y 
(PhGADA_VAS) ........................................................................................................ 42
8.1.6. Patient’s Gl obal Assessment of Arthri tis Pain (Visual Analog 
Scale)......................................................................................................................... 42
8.1.7. Patient’s Global Assessment of Di sease Act ivity 
(PaGADA_VAS) ........................................................................................................ 43
8.1.8. Health Assessment Questi onnaire -Disabilit y Index (HAQ- DI).................................. 43
8.1.9. Simplified Disease Act ivity Index (SDAI) .................................................................. 43
8.1.10. Clinical Disease Act ivity Index (CDAI) ...................................................................... 44
8.1.11. Medical Outcomes Study  36-Item Short Form  Heal th Survey ..................................... 44
8.1.12. MRI Imaging and Syno vitis Score .............................................................................. 44
8.2. Safety Assessments .................................................................................................... 45
8.2.1. Physical Examinat ions................................................................................................ 45
8.2.2. Vital Signs.................................................................................................................. 45
8.2.3. Electrocardiograms ..................................................................................................... 45
8.2.4. Clinical Safety  Laboratory  Assessments ..................................................................... 45
8.2.5. Suicidal  Ideat ion and Behavior Risk Monitoring ......................................................... 46
8.2.6. Tuberculosis Test ing and Monitoring .......................................................................... 47
8.2.7. Hepati tis B Test ing and Monitoring ............................................................................ 48
8.2.8. Hepati tis C Test ing and Monitoring ............................................................................ 49
8.3. Adverse Events and Serious Adverse Events .............................................................. 49
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 49
8.3.2. Method of Detecting AEs and SAEs ........................................................................... 50
8.3.3. Follow-up of  AEs and SAEs ....................................................................................... 50
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 50
8.3.5. Pregnancy ................................................................................................................... 50
8.3.6. Adverse Events of Special Interest .............................................................................. 51
8.3.7. Product Complaint s.................................................................................................... 52
8.4. Treatment of Overdose ............................................................................................... 52
8.5. Pharmacokinet ics........................................................................................................ 53
8.6. Pharmacodynamics ..................................................................................................... 53
8.7. Genet ics..................................................................................................................... 53
8.8. Biomarkers ................................................................................................................. 53
8.9. Immunogenicit y Assessments ..................................................................................... 54
8.10. Health Economics ....................................................................................................... 54
9. Statistical Considerations ......................................................................................... 55
9.1. Statistical Hypotheses .................................................................................................55
9.2. Sample Si ze Determinat ion......................................................................................... 55
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
69.3. Popul ations for Analyses ............................................................................................ 55
9.4. Statistical Analyses ..................................................................................................... 56
9.4.1. General Considerations ............................................................................................... 56
9.4.2. Primary Endpo int(s)................................................................................................... 58
9.4.3. Secondary  Endpo int(s)................................................................................................ 58
9.4.4. Exploratory  Endpo int(s).............................................................................................. 59
9.4.5. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 59
9.4.6. Evaluat ion of Immunogenicit y.................................................................................... 59
9.4.7. Other Safet y Analyses ................................................................................................ 60
9.4.8. Other Analyse(s) ......................................................................................................... 61
9.5. Inter im Analyses ......................................................................................................... 61
9.6. Data Monitoring Committee (DMC) ........................................................................... 62
10. Supporting Documentation and Operational Considerations ................................ 63
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 63
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 63
10.1.2. Financial Disclo sure................................................................................................... 63
10.1.3. Inform ed Consent Process .......................................................................................... 64
10.1.4. Data Protection ........................................................................................................... 64
10.1.5. Committees Structure .................................................................................................64
10.1.6. Disseminat ion of Clinical Study  Data ......................................................................... 65
10.1.7. Data Qualit y Assurance .............................................................................................. 65
10.1.8. Source Documents ...................................................................................................... 66
10.1.9. Study  and Si te Start and Cl osure ................................................................................. 66
10.1.10. Publicat ion Policy ....................................................................................................... 67
10.1.1 1.Invest igator Informat ion............................................................................................. 67
10.1.12. Long -Term  Sample Retent ion..................................................................................... 67
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 68
10.3. Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 71
10.3.1. Definit ion of AE......................................................................................................... 71
10.3.2. Definit ion of SAE ....................................................................................................... 72
10.3.3. Recording and Fo llow
-Up of AE and/or SAE ............................................................. 73
10.3.4. Reporting of SAEs ...................................................................................................... 74
10.4. Appendix 4: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 76
10.5. Appendix 5: Genetics .................................................................................................80
10.6. Appendix 6:  Recommended Laboratory  Testing for 
Hypersensi tivity Events .............................................................................................. 81
10.7. Appendix 7: Liver Safet y: Suggested Actions and Follow -up 
Assess ments ............................................................................................................... 83
10.8. Appendix 8: Provisio ns for Changes in Study  Conduct During 
Except ional Circumstances ......................................................................................... 86
10.9. Appendix 9: Abbreviat ions......................................................................................... 89
10.10. Appendix 10:  Country  Specific Requi rements ........................................................... 95
11. References ................................................................................................................. 96
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
71. Protocol Summary
1.1. Synopsis
Protocol Title: A Phase 2 Study  to Eval uate the Efficacy  and Safet y of LY3462817 in 
Parti cipants wi th Moderately to Severely Act ive Rheumatoid Arthritis
Short Title: A Phase 2 Study  to Eval uate the Efficacy  and Safet y of LY3462817 in Parti cipants 
with Moderately  to Severely  Active Rheumatoid Arthrit is
Rationale :
Rheumatoid arthrit is (RA) is a co mmo n, systemic autoimmune inflammatory  disease, 
characterized by  synovial inflammat ion leading to pain, swelling, st iffness, and progressive 
destruction and deformit y of small and large jo ints. Current treatment of RA prioritizes t imely 
initiation and m odificat ion of disease -modifying ant irheumatic drug ( DMARD )therapy  to bring 
patients to a target of sustained low disease act ivity(LDA) or remissio n. Patients ty pically begin 
treatm ent wi th oral convent ional synt hetic DMARDs (csDMARDs) ;but if the tr eatm ent target is 
not achieved, they  receive addi tional therapy  with biologic DMARDs (bDMARDs) or targeted 
synthetic DMARDs (tsDMARDs). However, 20 to 30% of patients with RA remain refractory to 
current therapies. There is a need for new, effect ive treatm ent opti ons in these patients.
LY3462817 is a humanized immunoglobulin (Ig) G1 monoclo nal ant ibody  that binds to and is an 
agonist to human programmed cell death protein 1 (PD -1). LY3462817 binding to PD -1 is 
expected to stimulate the physio logical immune inhibitory pathway to restore immune 
regul ation; thi s const itutes a novel approach to treat patients with autoimmune or 
auto-inflammatory diseases.
This study  aims to eval uate the efficacy of LY3462817 in adult participants with moderately to 
severely  active RA who have had an inadequate response to either csDMARD or to 
bDMARDs/ tsDM ARDS .  
Objectives and Endpoint s
Objectives Endpoints and Estimands
Comparison Groups: Placebo vs LY3462817
[time frame for endpoint evaluation: 12 weeks from randomization , unless stated otherwise ]
Primary
To evaluate the efficacy of LY3462817 in adult 
participants with moderately to severely active 
RAChange f rom baseline in DAS28- CRP.
The primary comparison will be assessed using a 
hypothetical efficacy estimand strategy to address the 
intercurrent event of early discontinuation where the mean 
change from baseline will be evaluated using only data up 
until discontinuation as if all subjects remained on 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
8randomized treatment.
Secondary
To describe the safety and tolerability of 
LY3462817 compared to placeboSafety assessments such as AEs, SAEs
To evaluate the effect of LY3462817 on 
measures of disease activity Proportio n of participants achieving ACR20, ACR50, 
and ACR70
Change f rom baseline for physician -assessed 
individual components:
o68 tender joint count
o66 swollen joint count
ophysician’s global assessment of disease activity 
(VAS)
Change f rom baseline for mean SDAI
Change f rom baseline for mean CDAI
To describe the effect of LY3462817 on PROs Change f rom baseline for:
Individual components of the ACR core set:
opatient’s global assessment of disease activity 
(VAS),
opatient’s global assessment of arthritis pain 
(VAS), and 
opatient’s assessment of physi cal function 
(HAQ -DI)
SF-36
To characterize the pharmacokinetics of 
LY3462817Observed drug concentration 
Abbreviations: ACR = American College of Rheumatology; ACR20 = 20% improvement in American College of 
Rheumatology criteria; ACR50 = 50% improvement in American College of Rheumatology criteria; 
ACR70 =70% improvement in American College of Rheumatology criteria; AE = adverse event; 
CDAI =Clinical Disease Activity Index; CRP = C -reactive protein; DAS28 = Disease Activity Score modified to
include the 28 diarthrodial joint count; HAQ -DI = Health Assessment Questionnaire -Disability Index; 
PRO =patient -reported outcome; RA = rheumatoid arthritis; SAE = serious adverse event; SDAI = Simplified 
Disease Activity Index; SF-36 = Study 36 -Item Sho rt Fo rm Health Survey; VAS = visual analog scale.
Overall Design
This is a Phase 2, proof -of-concept, pl acebo -controlled, double -blind, rando mized study in adult 
participants wi th moderately  to severely act ive RA who have had an inadequate response to 
csDM ARDs, or to bDMARDs /tsDMARDs . Parti cipants will be administered LY3462817 or 
placebo intravenously (IV)once every  4weeks ( Q4W ).
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
9Screening Period (Visit 1, Days -42 to -1)
Parti cipants will sign the informed consent document(s) at Visit 1, pri or to completion of any 
procedures. Participants will be evaluated for study eligibilit y ≤42days pri or to the baseline visit 
(Visit2).  
Period 1: Double -blind Treatment (Visits 2 to 6; 12 weeks)
At the baseline visit (Visit 2), participants who fulfill the el igibilit y criteria will be randomized to 
receive LY3462817 700 mg, LY3462817 300 mg, or placebo in an allocat ion rati o of 2:1:1.
The double -blind treatment period will establish the clinical efficacy and safet y of LY3462817. 
The study  will be evaluated for the primary  object ive at the end of the double -blind treatment 
period.
Period 2 (Visits 6 to 10; 12weeks)
In Peri od 2, participants assigned to LY346 2817 at baseline, and achieving low disease activit y 
(CDAI ≤10) at Week 14 will continue to receive LY346
2817 to assess safet y and tol erabili ty 
data and evaluate clinical act ivity with addi tional dosing. All other participants at Week 14, 
regardl ess of baseline treatment assignment, will receive standard of care treatment at the 
investigator ’s discret ion.  
Post-treatment Safety Follow -up Period (Visit sV801 and 802 ; 12 weeks)
Following Period 2, participants will be fo llowed posttreatm ent for 12weeks to assess safet y, 
study  drug exposure, and clinical disease act ivity.  
Disclosure Statement : This is a para llel, 3 -arm treatm ent study  that i s parti cipant -blinded and 
investigator -blinded.
Number of Participant s:
Approximately  80 parti cipants will be randomly  assigned to study  intervent ion. At the 
completion of the study , approximately 40 participants will have been rando mized to 
LY3462817 700 mg and 20 participants will have been randomized to LY 3462817 300 mg and 
placebo during the double -blind treatment .
Intervention Groups and Duration :
Parti cipants willreceive 1of the fo llowing study  intervent ions: intravenous LY3462817 300 mg, 
700 m g, or pl acebo every 4 weeks for 12 weeks. Participants assigned to LY346 2817 at baseline, 
and achieving low disease act ivity (CDAI ≤10) at Week 14 will cont inue to receive LY3462817 
through Week 24.  
Data Monitoring Committee: Nodata monitoring committee, but there will be an internal 
assessment committee.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
101.2. Schema
Notes:
For details about the study intervention doses, see Section 6.1.
Diagonal dashed arrows indicate transition to SOC therapy at Week 14. For details about SOC therapy, see 
Section 6.5.3.   
Abbreviations: Pbo = placebo; LDA = Low Disease Activity; LY=LY3462817; mg = milligrams; Q4W = once 
every 4weeks; SOC = Standard of Care; V = visit; W = week. 

CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
111.3. Schedule of Activities (SoA)
The SoA should be fo llowed for all participants enrolled in Study  KDAD. If participat ion in this study is affected by except ional 
circumstances, such as a pandemic or natural disaster, please refer to Section 10.8, Appendix 8 ,for addi tional guidance.
Study 
J1A-MC -KDADScreen Period 1: D ouble -blind treatment Period 2 EDPost- treatment 
follow -upComments
Day ± Visit Tolerance-42
to -1114
± 728
± 756
± 784
± 798
± 7112
± 7140
± 7168
± 7Any196
± 7252
± 7Visit 1 procedures may be conducted 
over more than 1 day as long as all tasks 
are completed within the tolerance 
window.
Week - 2 4 8 12 14 16 20 24 - 2836 or
ETV 
+ 12
Visit number V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 ET V801 V802
Procedures
Informed Consent XWritten informed consent must be 
obtained before any study procedures or 
assessments.
Inclusion and exclusion 
criteria, review and 
confirmX X
Demographics X
Preexisting conditions 
and medical history, 
including relevant 
surgical historyX
Prespecified medical 
history  (indication and 
history  of interest)X
Substance use (alcohol, 
caffeine, tobacco use)X X
Prior treatments for RA XAny previous therapy for RA in the past 
15 years that has now been 
discontinued .
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
12Study 
J1A-MC -KDADScreen Period 1: D ouble -blind treatment Period 2 EDPost- treatment 
follow -upComments
Day ± Visit Tolerance-42
to -1114
± 728
± 756
± 784
± 798
± 7112
± 7140
± 7168
± 7Any196
± 7252
± 7Visit 1 procedures may be conducted 
over more than 1 day as long as all tasks 
are completed within the tolerance 
window.
Week - 2 4 8 12 14 16 20 24 - 2836 or
ETV 
+ 12
Visit number V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 ET V801 V802
Procedures
Concomitant 
medicationsX X X X X X X X X X X X XFor concomitant medications of interest 
(such as background therapies),
additional data are collected.
Adverse events (AEs) X X X X X X X X X X X X XAE collection begins when ICF is 
signed (Section 10.3). For AESIs, 
additional data are collected 
(Section 8.3.6).
Participant -Reported Outcomes (Electronic)
Patient’s Global 
Assessment of Arthritis 
Pain (VAS) X X X X X X X X X X X X XAdminister before any clinical 
assessments and dosing
Health Assessment 
Questionnaire -
Disability Index (HAQ -
DI)X X X X X X X X X X X X XAdminister before any clinical 
assessments and dosing
Patient's Global 
Assessment of Disease 
Activity  
(PaGADA _VAS)X
X X X X X X X X X X X XAdminister before any clinical 
assessments and dosing
Medical Outcomes 
Study 36 -Item Short 
Form Health Survey 
(SF-36 v2, Acute)X X X X XAdminister before any clinical 
assessments and dosing
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
13Study 
J1A-MC -KDADScreen Period 1: D ouble -blind treatment Period 2 EDPost- treatment 
follow -upComments
Day ± Visit Tolerance-42
to -1114
± 728
± 756
± 784
± 798
± 7112
± 7140
± 7168
± 7Any196
± 7252
± 7Visit 1 procedures may be conducted 
over more than 1 day as long as all tasks 
are completed within the tolerance 
window.
Week - 2 4 8 12 14 16 20 24 - 2836 or
ETV 
+ 12
Visit number V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 ET V801 V802
Procedures
Physical Evaluation
Height X
Weight X X X X
Vital Signs (BP, PR, T) X X X X X X X X X X X X XSupine or sitting blood pressure and PRs
obtained at approximately same time as 
the ECG, prior to blood sampling.
Complete physical 
examinationX X XExcludes pelvic, rectal, and breast 
examinations.
Symptom -directed 
physical examinationX X X X X X X X X XPerformed at the discretion of the 
investigator. Assess prior to dosing .
12-lead ECG (local) X X X XParticipants to be supine for at least 
5minutes before ECG and remain 
supine but awake during ECG. Assess 
prior to blood sampling.
Chest x- ray 
(posterior -anterio r and 
lateral view; local)XDocumentation of radiologic 
reports/films taken within 3 months 
prior to screening is acceptable. Lateral 
view is optional or according to local 
guidelines.
MRI (Hand/Wrist) X XPerformed only after the all eligibility 
criteria are met except: criteri on6. 
Evaluate the same hand/wrist at 
screening and Week 12 prior to dosing .
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
14Study 
J1A-MC -KDADScreen Period 1: D ouble -blind treatment Period 2 EDPost- treatment 
follow -upComments
Day ± Visit Tolerance-42
to -1114
± 728
± 756
± 784
± 798
± 7112
± 7140
± 7168
± 7Any196
± 7252
± 7Visit 1 procedures may be conducted 
over more than 1 day as long as all tasks 
are completed within the tolerance 
window.
Week - 2 4 8 12 14 16 20 24 - 2836 or
ETV 
+ 12
Visit number V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 ET V801 V802
Procedures
Health Care Professional RA Assessments (Electronic)
Clinician -Administered 
Tender/Swollen Joint 
Count (TSJC) (68/66)X X X X X X X X X X X X XCollected via an electronic tablet device. 
These joint counts will be performed by 
the Joint Assessor (Section 6.3). 
Determine prior to dosing
Physician's Global 
Assessment of Disease 
Activity  
(PhGADA_VAS)X X X X X X X X X X X X X Determine prior to dosing
Clinician-Administered Assessments (Paper)
C-SSRS 
Screening/BaselineXAdminister before any clinical 
assessments and dosing
C-SSRS Since Last 
AssessedX X X X X X X X X X X XAdminister before any clinical 
assessments and dosing
Self-harm Supplement 
FormX X X X X X X X X X X X X
Self-Harm Follow -Up 
FormX X X X X X X X X X X X X
Laboratory Tests and Sample Collections
Hematology X X X X X X X X X X X X Collect prior to dosing
Clinical Chemistry X X X X X X X X X X X XIn addition to scheduled assessments, 
these laboratory tests may also be 
performed as clinically indicated.
Collect prior to dosing .
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
15Study 
J1A-MC -KDADScreen Period 1: D ouble -blind treatment Period 2 EDPost- treatment 
follow -upComments
Day ± Visit Tolerance-42
to -1114
± 728
± 756
± 784
± 798
± 7112
± 7140
± 7168
± 7Any196
± 7252
± 7Visit 1 procedures may be conducted 
over more than 1 day as long as all tasks 
are completed within the tolerance 
window.
Week - 2 4 8 12 14 16 20 24 - 2836 or
ETV 
+ 12
Visit number V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 ET V801 V802
Procedures
Urinaly sis X X X X X X XIn addition to scheduled assessments, 
these laboratory tests may also be 
performed as clinically indicated.
Collect prior to dosing .
Serum pregnancy XFor all women of childbearing potential 
(Section 10.4).
Urine pregnancy
(local)X X X X X X X X X XDetermine results prior to dosing
Follicle Stimulating 
Hormone (FSH)XFor women who are considered 
postmenopausal to confirm 
postmenopausal status.
C-Reactive Protein, 
high-sensitivity 
(hsCRP)X X X X X X X X X X X X XCollect prior to dosing
Erythrocy te 
sedimentation rate 
(ESR)X X X X X X XCollect prior to dosing
Rheumatoid factor (RF) X X X X X X X Collect prior to dosing
Anticyclic citrullinated 
peptide (anti -CCP)X X X X X X XCollect prior to dosing
Soluble PD -1 X X X X X X X X X X Collect prior to dosing
Soluble PD-L1 X X X X X X X X X X Collect prior to dosing .
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
16Study 
J1A-MC -KDADScreen Period 1: D ouble -blind treatment Period 2 EDPost- treatment 
follow -upComments
Day ± Visit Tolerance-42
to -1114
± 728
± 756
± 784
± 798
± 7112
± 7140
± 7168
± 7Any196
± 7252
± 7Visit 1 procedures may be conducted 
over more than 1 day as long as all tasks 
are completed within the tolerance 
window.
Week - 2 4 8 12 14 16 20 24 - 2836 or
ETV 
+ 12
Visit number V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 ET V801 V802
Procedures
Tuberculosis (TB) test XSee Section 8.2.7 for details of TB 
testing. Participants will return 48 to 
72hours after a tuberculin test (TST) for 
their test results. If the QuantiFERON® -
TB Gold test or T -SPOT® TB test is 
available, either test may be used 
instead of the PPD TB test. The 
QuantiFERON® -TB test is done 
centrally or locally; the T -SPOT® TB 
test must be done locally.
Human 
immunodeficiency 
virus (HIV) screening 
testsX
Hepatitis C virus 
(HCV) screening testsX
Hepatitis B virus 
(HBV) screening testsXIncludes HBsAg and anti -HBc.
Hepatitis B virus 
(HBV) DNAX X X X XAny enrolled participant who is 
HBcAb+ will undergo monitoring of 
HBV DNA during the study treatment.
Flow cytometry panel X X X X X X X Includes: TBNK , collect prior to dosing
Cytokine panel X X X X X X X Collect prior to dosing
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
17Study 
J1A-MC -KDADScreen Period 1: D ouble -blind treatment Period 2 EDPost- treatment 
follow -upComments
Day ± Visit Tolerance-42
to -1114
± 728
± 756
± 784
± 798
± 7112
± 7140
± 7168
± 7Any196
± 7252
± 7Visit 1 procedures may be conducted 
over more than 1 day as long as all tasks 
are completed within the tolerance 
window.
Week - 2 4 8 12 14 16 20 24 - 2836 or
ETV 
+ 12
Visit number V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 ET V801 V802
Procedures
Immunoglobulin panel X X X X XIncludes: IgG, IgM, and IgA
Collect prior to dosing
Pharmacokinetic 
samplesX X X X X X X X X XCollect prior to dosing
Immunogenicity 
samplesX X X X X X X XCollect prior to dosing
Receptor occupancy X X X X X X X X X Collect prior to dosing
Peripheral helper 
TcellsX X X X X X X X XCollect prior to dosing
Stored samples
Genetics sample X Collect prior to dosing
Explo ratory  biomarker 
samplesX X X X X X X X X XSee Section 10.2 for details
Collect prior to dosing
Randomization and dosing
Randomization X
Administer study drug X X X X X X XDuring Week s16 - 24 administer study 
drug only if participant achieved l ow 
disease activity at Week 14 .
Abbreviations: AESI = adverse event of special interest; anti-HBc = hepatitis B core antibody; BP = blood pressure; C-SSRS = Columbia -Suicide Severity 
Rating Scale; ECG = electrocardiogram ; ED = early discontinuation visit; ET = early termination; ETV = early termination visit; HBcAb+ =hepatitis B core 
antibody positive; HBsAg = hepatitis B surface antigen; ICF = informed consent form; IgA = immunoglobulin A; IgG = immunoglobulin G; 
IgM =immunoglobulin M; MRI = magnetic resonance imaging; PD-1 = progr ammed cell death protein 1; PD -L1 = programmed cell death ligand 1; 
PPD =purified protein derivative; PR=pulse rate; RA= rhe umatoid arthritis; T =temperature ; TBNK =T cells, B cells, natural killer cells; V = visit ; 
VAS =visual analog scale .
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 1 A -M C -K D A D( b) 
1 8 2. I ntr o d ucti o n 
2. 1. St u d y R ati o n ale 
R he u m at oi d art hritis 
R he u mat oi d art hrit is ( R A) is a c o m m o n, s y ste mic a ut oi m m u ne i nfla m mat or y  di sease, 
c haracterize d b y  s y n o vial i nfla m mat i o n lea di n g t o pai n, s welli n g, st iff ness, a n d pr o gressi ve 
destr ucti o n a n d def or mit y of  s mall a n d lar ge j o i nt s. Patie nts e x perie nce i m paire d p h ysical 
f u nct i o n, s ocial partici pati o n, a n d healt h- relate d q ualit y of  l ife. Pati e nts al s o ha ve i ncrease d ri s k 
of  si g nifica nt n o n m usc ul o s keletal  c o m or bi di ti es ( M utr u et al. 1 9 8 5; D ora n et al . 2 0 0 2; Si h v o ne n 
et al . 2 0 0 4; A vi ña -Z u bieta e t al . 2 0 0 8, 2 0 1 2; C h oi et al . 2 0 1 3 ; Ki m et al . 2 0 1 3; Lee a n d P o pe 
2 0 1 4; Pi cer n o et al . 2 0 1 5; Si m o n et al . 2 0 1 5; O g die et al . 2 0 1 8 ). 
C urre nt tre at me nt of R A 
C urre nt treat me nt of R A pri oritizes t i mel y i nit iati o n a n d m o dificat i o nof  disease -m o dif yi n g 
a nt ir he u mat ic dr u gs ( D M A R D )t h era p y  t o bri n g pati e nts t o a tar get of s ustai ne d l o w disease 
acti vit y ( L D A) or re missi o n ( Si n g h et al. 2 0 1 6; S m ole n et al. 2 0 2 0 ). Ac hie ve me nt of t hese 
tar gets i m pr o ves s h ort -a n d l o n g -t er m  pat ie nt  healt h o ut c o m es, i ncl u di n g pre ve nt i o n of 
pr o gressi ve, irre versi ble str uct ural j o i nt  d a m a ge ( Mai ni et al . 2 0 0 4; S m ol e n et al . 2 0 2 0). 
T he treat me nt tar get ca n be met i n m ost patie nts wit h t he t hera pe utic o pti o ns c urre nt l y a vaila ble , 
w hic h i ncl u de c o n ve nti o nal s y nt hetic D M A R D S ( cs D M A R Ds ), bi o l o gi c D M A R Ds 
( b D M A R Ds), a n d tar gete d s y nt hetic D M A R Ds (ts D M A R Ds ). H o we ver, 2 0 t o 3 0 % of t he 
pati e nts wi t h  R A re m ai n refract or y  t o c urre nt t hera pies. F or t hese pat ie nt s, ne w treat me nt o pti o ns 
are nee de d ( S m ol e n et al . 2 0 2 0 ). 
St u d y K D A D 
T his st u d y ai ms t o e val uate t h e efficac y of L Y 3 4 6 2 8 1 7 i n a d ult partici pa nts wit h m o deratel y t o 
se verel y  act i ve R A w h o ha ve ha d a n i na de q uate res p o nse t o cs D M A R Ds, or t o 
bD M A R Ds /ts D M A R Ds.   
2. 2. B ac k gr o u n d 
L Y 3 4 6 2 8 1 7 is a h u ma nize d i m m u n o gl o b uli n (I g) G 1 m o n ocl o nal a nt i b o d y  t hat bi n ds t o a n d is a n 
a g o nist t o h u ma n pr o gra m me d cell deat h pr otei n 1 ( P D -1).  
 
 
 
 
P D -1 p at h w a y i n a ut oi m m u ne dise ase s
Pr o gra m me d cell deat h pr otei n 1e x pressi o n was f o u n d t o be hi g h a n d pr o gra m me d cell deat h 
li ga n d 1 ( P D -L 1 )( w hic h bi n ds t o P D -1) e x pressi o n l o w i n t he s y n o vi u m of pat ie nt s wi t h  R A 
( G u o et al. 2 0 1 8). C haracterizat i o n of pat h o ge nic, hi g hl y  P D - 1- e x pressi n g T -cell s u bsets wit hi n C CI 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
19the synovium o f patients with RAshowed them  to be uniquely  poised to prom ote B -cell 
responses and ant ibody  producti on (Rao et al. 2017). Additionally, patient s with RAtend to have 
autoantibodies to PD -L1 and increased so luble PD -1 (sPD -1) and PD- L1 (Wan et al. 2006), all o f 
which correlate with disease activit y.  
Evidence of the PD -1 pathway  pathol ogy having a si gnificant rol e in autoi mmune diseases has 
also been demo nstrated in psoriasis (Gulat i et al. 2015), psori atic arthritis (Bommarito et al. 
2017), gi ant cell vasculit is (Zhang et al. 2017), mult iple sclerosis (Trabattoni et al. 2009), and 
systemic sclerosis (Fukasawa et al. 2017).
LY3462817
Inform ation on t he safet y, tolerabilit y, pharmacokinet ics (PK), and pharmacodynamics (PD) of 
LY3462817 comes from the com pleted study  J1A-MC-KDAB (KDAB) and fro m the ongoing 
study  J1A-MC-KDAC (KDAC).
Study Study design Population Study interventions
KDAB Single ascending dose, first in 
human, Phase 1Healthy  participants LY3462817: 0.1, 0.4, 2, 8, 30, 120, 350, 
or 700 mg IV
120 mg SC
KDAC Double -blind, multiple ascending 
dose, placebo -controlled, Phase 1b. Participants with 
psoriasisLY3462817: 75, 300, or 700 mg Q4W IV
for 12 Weeks
Abbreviations: IV = intravenous; Q4W =once ever y 4weeks ; SC = subcutaneous .
As of 02 Sept ember 2020, 47healt hy participants in Study KDAB have received LY3462817. 
Six participants received 75mgand 7 participants have received 300mg LY3462817 in Study  
KDAC .
No deaths or serious adverse events (SAEs) were reported so far in these studies, and no 
participants di scont inued because of an adverse event (AE). Overall, no cl inically  significant 
safet y concerns were i dentified wit h single- dose intravenous ( IV)administration of LY3462817 
up to 700 mg and subcutaneous ( SC)administration of LY3462817 120 mg . Also ,no clinically 
significant safet y concerns have been ident ified with mult iple-dose administrati on of  LY3462817 
up to 300mgin Study  KDAC .
The PK of LY3462 817 ha sbeen evaluated following single doses (Study  KDAB) and a small 
subset of the 75 m g mu
ltiple dose (Study  KDAC) cohort. Nonlinear disposi tion that i s 
characterist ic of many m onoclonal antibodies was observed at lower doses and the PK was 
approximately  dose -proporti onal at doses equal  to and greater than 30 mg. Based on 
nonco mpart mental analysis, in the dose linear range ( ≥30mg), LY3 462817 has estimated 
clearance of 10.9 mL/hr, volume of distribution of 3.9 L, and a terminal half -life of 
approximately  10 days. A com parison of exposure fro m the single dose 120 mg IV and SC 
cohorts indicates a bioavailabilit y of approximately  60%. Acros s the IV cohorts, the median time 
to reach C maxranges between 2 to 8 hours while fo r 120 m g SC, the m edian is approximately  9.5 
days. Given the limit ed PK data in the mult iple dose cohort (75 mg IV once every 4 weeks 
[Q4W ]), resul ts were not stati stically analyzed. Additionally , in Study  KDAB, receptor 
occupancy  (RO) and sPD -1 concentrations in healt hy vo lunteers fo llowing single IV doses of 
LY3462817 were collected and analyzed. Together, both are interpreted as measures of target 
engagement. Across all dose levels tested, RO and sPD- 1 increase din both extent and duration 
with increasing dose level.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
20In Study KDAC, the 75 -mg cohort (N=8) and 300 -mg cohort (N=10) were fully enrolled. By  the 
data cutoff date, some subjects had received a minimum o f 2 doses, while so me subjects had 
received a maximum of 4 doses (every -4-week dosing schedule).   
Adecisio n wasmade to dose escalate to 700 m gon 08 
September 2020. Given the overall safet y 
profile of LY3462817 to date, the sponsor believes th edecisio n to dose escalate to 700 mg in 
Study  KDAC provi des sufficient safet y data to init iate this study , KDAD. 
Adetailed description o f the chemistry , pharmaco logy, 
toxicology, efficacy , and safet y of 
LY3462817 is provided in the Invest igator’s Brochure (IB).
2.3. Benefit/Risk Assessment
Manageable risks associated with most therapeutic monoclonal ant ibodies are the potential for 
infusio n-related hypersensit ivity and cy tokine rel ease reacti ons. The infusio ns in this study  will 
be administered at a controlled rate, the study  partici pants will  be m onitored cl osely , and 
adjustm ents in the infusio n rate will be made and/or the infusio n stopped, if indicated. Addit ional 
inform ation regarding infusion react ion and hypersensit ivity management options is located in 
Secti on8.3.6 .
No clinically  significant safet y conc erns (including infusio n or inject ion site reactions) were 
observed in Study KDAB, or have been observed in the S tudy KDAC as of 02 September 2020.
The efficacy of LY3462817 in RA has not been established. Participants may benefit by 
receiving personal health informat ion from the physical examinat ions and fro m other routine 
safet y assessments performed in this study . 
In summary, in the context of the cumulative knowledge for LY3462817, the benefit/risk balance 
for this study  is assessed to be acceptable for testing in Phase 2.
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected AEs of LY3462817 may be found in the IB. 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
213. Objectives and Endpoints
Objectives Endpoints andEstimands
Comparison Groups: Placebo vs LY3462817
[time frame for endpoint evaluation: 12 weeks from randomization , unless stated otherwise ]
Primary
To evaluate the efficacy of LY3462817 in adult 
participants with moderate lyto severe lyactive 
RAChange f rom baseline in DAS28 -CRP
The primary comparison will be assessed using a 
hypothetical efficacy estimand strategy to address the 
intercurrent event of early discontinuation where the mean 
change from baseline will be evaluated using only data up 
until discontinuation as if all subjects remained on 
randomi zed treatment.
Secondary
To describe the safety and tolerability of 
LY3462817 compared to placeboSafety assessments such as AEs, SAEs
To evaluate the effect of LY3462817 on 
measures of disease activityProportio nof participants achieving ACR20, ACR50, 
and ACR70
Change f rom baseline for physician -assessed 
individual components:
o68 tender joint count
o66 swollen joint count
ophysician’s global assessment of disease activity 
(VAS)
Change f rom baseline for mean SDAI
Change f rom baseline for mean CDAI
To describe the effect of LY3462817 on PROs Change f rom baseline for:
Individual components of the ACR core set:
opatient’s global assessment of disease activity 
(VAS),
opatient’s global assessment of arthritis pain 
(VAS), and 
opatient’s assessment of physical function (HA Q-
DI)
SF-36
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
22To characterize the pharmacokinetics of 
LY3462817Observed drug concentration
Exploratory
To explore the effect of LY3462817 on other 
measures of disease activityProportio n of participants achieving LDA or remission 
using the following measures: DAS28 -CRP, 
DAS28 -ESR, SDAI, and CDAI atall time points 
collected   
Change f rom baseline in the RAMRIS synovitis score 
by MRI imaging
To explore the durability of effect of 
LY3462817Proportio n of participants achieving LDA (with the 
following measures : DAS28 -CRP, DAS28 -ESR, 
SDAI, and CDAI) at Week 12 and maintain ingLDA 
through Week 2 4
Proportio n of participants that achieve remission (with 
the following measures: DAS28 -CRP, DAS28 -ESR, 
SDAI, and CDAI) at Week 12 and maintain ing 
remission through Week 24
Abbreviations: ACR = American College of Rheumatology; ACR20 = 20% improvement in American College of 
Rheumatology criteria; ACR50 = 50% improvement in American College of Rheumatology criteria; 
ACR70 =70% improvement in American College of Rheumatology criteria; AE = adverse event; 
CDAI =Clinical Disease Activity Index; CRP = C -reactive protein; DAS28 = Disease Activity Score modified to 
include the 28 diarthrodial joint count; ESR = erythrocyte sedimentation rate; HAQ -DI = Health Assess ment 
Questionnaire -Disability Index; LDA = low disease activity; MRI =magnetic resonance imaging; 
PRO =patient -reported outcome; RA = rheumatoid arthritis; RAMRIS =Rheumatoid Arthritis Magnetic 
Resonance Imaging Scoring system; SAE = serious adverse eve nt; SDAI = Simplified Disease Activity Index; 
SF-36 = Study 36 -Item Short Form Health Survey; VAS = visual analog scale.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
234. Study Design
4.1. Overall Design
This is a Phase 2, proof -of-concept, pl acebo -controlled, double -blind, rando mized study in adult 
participants wi th moderately  to severely act ive RA who have had an inadequate response to 
csDMARDs, or to bDMARDs /tsDMARDs .Parti cipants will be administered LY3462817 or 
placebo IV Q4W.
Screening Period ( Visit 1, Days -42 to -1)
Parti cipants will sign the informed consent document(s) at Visit 1, pri or to completion of any 
procedures. Participants will be evaluated for study  eligibilit y ≤42days pri or to the baseline visit 
(Visit2).  
Period 1: Double -blind Treatment (Visits 2 to 6; 12 weeks)
At the baseline visit ( Visit2), parti cipants who fulfill the eligibilit y criteria will be rando mized to 
receive LY3462817 700 mg, LY3462817 300 mg, or placebo in an allocat ion ratio of 2:1:1.
The double -blind treatment period will establish the clinical efficacy and safet y of LY3462817.
The study  will be evaluated for the primary  object ive at the end of the double -blind treatment 
period.
Period 2(Visits 6to 10; 12weeks)
Data from a Study  KDAC interim analysis that includes Week 12 data fro m participants in the
KDAC 700 -mg cohort, must be reviewed prior to a participant proceeding to Period 2 in Study 
KDAD .
At Week 14, parti cipants will be evaluated for clinical benefit. 
Parti cipants assigned to LY346 2817 at baseline, and achieving low disease act ivity (CDAI ≤10) 
at Week 14 will continue to receive LY3462817 at the rando mized dose through Week 24 to 
assess safet y and tol erabili ty and evaluate efficacy .  
All other participants at Week 14, regardless of baseline treatment assignment , will stop study  
drug infusi ons and shoul dreceive standard of care treatment at the invest igator ’s discreti on.
Posttreatment Safety Follow -up Period ( Visits V801 and 802; 12 weeks )
Following Period2, participants will be fo llowed posttreatm ent for 12weeks to assess safet y, 
study  drug exposure, and clinical disease act ivitymeasures .Parti cipants who di scontinue the 
study  interventi on per Secti on7will have their last visit at 12 weeks fro m the last administrati on 
of the study  intervent ion.
4.2. Scientific Rationale for Study Design
Appropriateness of study population
Patients wi th RA are treated with the oral  csDMARD methotrexate ( MTX
)as the first -line 
therapy either by  itself or in combinat ion with other therapi es (Sm olen et al . 2020). If the 
treatm ent target i s not achi eved wi th the ini tial csDMARD strategy ,treatm ent m odificati on of ten 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
24involves use of bDMARDs , including tumor necrosis factor -α (TNF -α)inhibitors, or targeted 
synthetic tsDMARDs ,in combinat ion with csDMARDs (Sm olen et al . 2020).
LY3462817 is being invest igated to modulate theunderlying immune dysregulat ion in the PD -1 
pathway  for the treatm ent of RA. Enrolling a mixed RA population who have had an inadequate 
response to csDMARDs, or to bDMARDs /tsDMARDs woul d allow patients wi th inadequate 
response to the current standard of c are for RA across the disease spectrum to be included in the 
study .
Duration of treatment period and post -treatment follow -up
The pl acebo -controlled treatment period (Period 1) last s12 weeks. Participants rando mized to 
LY3462817 at bas eline can cont inue to receive treatment though Week 24 if achieving low 
disease act ivity by Week 14. Per current RA treatment guidelines (Smo len et al . 2020), therapy  
shoul d be adjusted if no improvement is achieved by approxim ately ≤3 months within ini tiation, 
or if the target has not been reached by 6 months (Smo len et al . 2020). All participants
rando mized to placebo, and participants randomized to LY34 62817 not achiev inglow disease 
activit y by Week 14 should be switch to SO CRA therapy 
atthe invest igator ’s discretion. The 
length of the study  placebo -controlled period fallswithin those gui delines.
The 1 2-week fo llow -up durati on after 24 weeks of treatment is considered to be sufficient to 
evaluate safety  and to expl ore the durabilit y of bio marker and clinical disease activit y changes 
achieved during the 24 -week treatment period. Participants with disease activit y that require any 
other treatment may  discontinue the study  at any  time ( Secti on7.2).
Change from baseline in DAS28- CRP as the primary endpoint
The primary  endpoint of this study  is the change from  baseline at Week 12 in the Disease 
Activity Score - C-reactive protein (DAS28 -CRP )(Secti ons3and 8.1.1 )and is a continuous 
measure that enabl esevaluat ion across m ultiple time points.
MRI
Magnet ic resonance imaging (MRI) allows detailed assessment of the synovial jo int. Magnet ic 
resonance imaging features are frequently used as outcome measures in RA clinical trials. The 
Outcom e Measures in Rheumatoid Arthrit is Clinical Trials ( OMERACT )RA MRI Scoring 
system  (RAMRIS) outlines semiquant itative scoring of 5 RA pathol ogies: bone erosi ons, j oint 
space narrowing, synovit is, tenosynovit is, and bone marrow edema in the wrist and 
metacarpophalangeal jo ints.
The primary  interest in this study is to evaluate the effect iveness o f LY3462817 in reducing 
inflammat ion in the jo ints. Enrolling study  parti cipants wi th active syno vitis as determine dby 
MRI will support overall evaluat ion of LY3462817 in reducing inflammat ion. Exploratory  
evaluat ion of a change in RAMRIS syno vitis score at Week 12 will provi de an object ive measure 
of reducti on in inflammat ion.
4.3. Justification for Dose
In thi s study , 2 dose l evels o f LY3462817 will be evaluated: 300 mg and 700 mg.These dose 
levels were selected based on preclinical pharmacology  and toxi cology data, and available 
clinical PK, target engagement ,and safet y data.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
25In Study  KDAB, s ingle LY3462817 IV doses of 350 and 700 mg have been evaluated in healthy 
subjects wi th no clinical significant safet y concerns. The ongoing Study  KDAC, is designed to 
evaluate mult iple doses ( 4total doses ) of 75 m g, 300 mg,and 700 mg ofLY3462817 IV Q4W in 
participants with psori asis. The data from these studies and the plan to init iate KDAD is 
discussed in Section 2.2.
From available human PK and preclinical mo nkey toxicology data, the estimated margins of 
safet y for 300 m g and 700 m g LY3462817 IV Q4W are≥24 and >10- fold, respect ively , based on 
both dose and steady -state exposure mult iples. 
The pl anned dose l evels were alsoselected to evaluate an exposure range that is ant icipated to be 
pharmaco logically act ive. Receptor occupancy  was used as a surrogate for pharmaco logical 
activit y to hel p assess dose l evels that saturate the target over the planned dosing interval. Doses 
of 
350 mg and 700 mg have both been shown to saturate the receptor in plasma over 4 weeks and 
longer. However, significant uncertai nties exist in transl atingRO profile in plasma to tissue with 
respect to drug concentration and receptor densit y(Chen et al. 2015 ;Rao et al . 2017). The 2dose 
levels help account for the se uncertainties , both of which directionally point to a decrease in 
extent and duration in tissue RO rel ative to plasma. Addit ionally , inclusi on of 2dose l evels in 
KDAD will allow for a direct comparison with the corresponding dose levels in KDAC for 
assessing the impact, if any, of disease state on PK, RO, and sPD- 1. If there is impact, having an 
additional dose level  in KDAD will provide more data and confidence when project ing forward 
to a dose level or regimen ranging study .
4.4. End of Study Definition
A participant is considered to have co mpleted the study  if he/she has co mpleted all requi red 
phases of the study  including the last scheduled procedure shown in the SoA (Section 1.3).
The end o f the study  is defined as the date of last scheduled procedure shown in the SoA for the 
last parti cipant in the tri al globally.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
265. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted .
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1.Are ≥18years of age, at the time of signing the informed consent
Type of Participant and Disease Characteristics
2. H ave a diagnosis of adult onset RA as defined by the 2010 American Co llege of 
Rheumatology  (ACR)/European League Against Rheumat ism (EULAR )classificat ion 
criteria (Aletaha et al. 2010) for at least 3 m onths pri or to screening
3. H ave moderately  to severely act ive RA defined by the presence of ≥6 swo llen jo ints 
(based on 66 jo int count) and ≥6tender jo ints (based on 68 jointcount) at screening and 
baseline .The di stal interphalangeal jo int shoul d be evaluated but not included in t he total  
count to determine eligibilit y
4. H ave at least 1 of the following: 
positive test results for rheumatoid factor or anti -citrullinated peptide ant ibodies at 
screening, 
OR 
previous radiographs document ing bony erosions in hands or feet consistent w ith RA
5.Have C -react ive protein (CRP) >1.2 times upper limit of normal (ULN) per the central
laboratory  at screening
6.Have activesyno vitis in≥1 joint in hand s or wri sts atscreening as dem onstrated by  a 
MRI synovit is RAMRIS score (Østergaard et al. 2017) of ≥1 determined fro m central  
reading of images
7.Vaccinat ions of study  subjects should be up to date per regional and nat ional guidelines, 
specifically influenza, pneumo nia, and zoster. All should be administered ≥30days 
before rando mizat ion and no live v accines shoul d be used wit hin 3 months of 
rando mizat ion  
8. H ave clinically  acceptable central  laboratory  test resul ts at screening (retesting is allowed 
for hematol ogy and chemistry ), as assessed by  the investi gator, including :
Hem atology
absolute neutrophi l count ≥1.5 × 109/L (≥1.5 × 103/µL or ≥1.5 GI/L)
platelet count ≥100 × 109/L (≥100 × 103/µL or ≥100 GI/L)
hemoglo bin level  ≥10.0 g/dL
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
27lymphocy te count >500 cells/µL (>0.50 × 103/µL or >0.50 GI/L)
total leukocy te count ≥3.0 × 109/L (≥3.0 × 103/µL or ≥3.0 GI/L)
Clinical chemistry  test resul ts
serum  creat inine, alanine aminotransferase (ALT), and aspartate aminotransferase 
(AST) l evels ≤2× ULN
total bilirubin level (TBL) and alkaline phosphatase (ALP) <1.5 × ULN (patients 
with Gilbert’s syndrom e must have serum di rect bili rubin <1.5 m g/dL)
Concomitant Therapy
9.Dem onstrated an inadequate response to, orloss of response or intol erance to :
at least 1csDMARD treatm ent
OR
at least 1bDMARD/tsDMARD treatment 
This is defined as signs and symptoms of persistentl y active di sease despi te a history  of
treatm ent wi that least1of the fo llowing: azathioprine, MTX , hydroxychl oroquine, 
leflunomide, sulfasalazine, bDMARDs, or tsDMARDs
10.The fo llowing therapi es are permitted during the study , if the dose i s stable for ≥4weeks 
prior to the screening MRI :
parenteral  MTX up to 20 mg/week OR oral MTX up to 25 mg/week. S ubjects on 
MTX shoul d receive supplementation with fo lic acid according to local standard of 
care
hydroxychloroquine up to 400 mg/day
leflunomide up to 20 mg/d ay
oral sulfasalazine up to 3000 mg/day 
oral prednisone ≤10 mg daily  or other equivalent corti costeroi d dose
Contraception
11.To parti cipate in the study , participants must agree to the r eproductive and contraceptive 
agreem ents and guidance provided in Sect ion10.4, Appendix 4.  
Contraceptive use by men or women should be consistent with local regulat ions for those 
participat ing in clinical studies.
Informed Consent
12.Capable of giving signed informed consent as described in Appendix 1 which includes 
compliance wi th the requi rements and restri ctions listed in the informed consent form 
(ICF) and in this protocol
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
285.2. Exclusion Criteria
Parti cipants are excluded fro m the study  if any of the fo llowing cri teria apply:
Medical Conditions
13.Class IV RA according to ACR revised response criteria
14.Have an abnormalit y in the 12 -lead el ectrocardi ogram  (ECG) that, in the opinio n of the 
investigator, increases the ri sks associated with participat ing in the study
15.Have presence of 1 or more si gnificant concurrent medical condit ions per invest igator 
judgment, including but not limit ed to the fo llowing: poorly  controlled diabetes or 
hypertensio n; chronic kidney disease st age IIIb, IV, or V; symptomat ic heart failure (New 
York Heart Associat ion class II, III, or IV); myocardial infarction or unstable angina 
pectori s within the past 12 months prior to randomizat ion; severe chronic pulmo nary 
disease (e.g., requiring oxy gen th erapy );andmajor chronic inflammatory  disease or 
connective tissue disease other than RA
16.Have a history  of chronic alcoho l abuse, IV drug abuse or illicit drug abuse wit hin 1 year 
before screening.
Note: Marijuana use isprohibited during participatio n in this study , regardless o f local 
laws or if used for medical purposes. Cannabidio l (CBD) products may  be used during 
the study  if they are derived exclusively  from hemp. Parti cipants who use hem p-based 
CBD products must b e on a stabl e dose for at l east 10 day s prior to randomization, and 
participants m ust rem ain on that stabl e dose during the study .
17.Have a Co lumbia -Suicide Severi ty Rating Scale (C -SSRS) i deation within 1 month prior 
to screening or any  suicidal behavior wi thin 3 m onths pri or to screening and eit her 
ideat ion or sui cidal behavior during screening prior to Visit 2
18.Have donated blood of more than a single unit of blood within 4 weeks before 
rando mizat ion (Vi sit 2) or intent to donate blood during the course of the study
19.Have a diagnosis or history  of malignant di sease wi thin 5 years prior to baseline, with the 
exceptions of:
basal cell or squamous epithelial carcino mas of the skin that have been 
resected with no evidence of metastatic disease for 3 y ears, or 
cervical carcino ma in situ, with no evidence o f recurrence within the 5 years 
prior to baseline
20.Have presence of confirmed cervical dysplasia
21.Have had any  surgical  procedure (except for minor surgery  requi ring local or no 
anesthesia and without any  complications or sequelae) within 12 weeks prior to 
screening, or any  planned surgi cal procedure scheduled to occur during the study
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
2922.Have received a Bacillus Calmette -Guerin (BCG) vaccination or BCG treatm entwithin 
12months of screening; or received any other live vaccine(s) (i.e., live attenuated) within 
3 months of screening, or intend to receive a live vaccine during the study
23.Have had any  of the f ollowing t ypes o f infect ion wit hin 3 mo nths of screening or 
develops any o f these infect ions before the ra ndomizat ion visit:
oSerious (requi ring hospi talizat ion, and/or IVor equivalent oral ant ibiotic treatment) 
oOpportuni stic (as defined in Wint hrop et al . 2015) 
oHerpes zoster is considered act ive and ongoing until all vesicles are dry  and 
crusted over
oChroni c (durati on of  symptom s, signs, and/or treatment of 6 weeks or longer) 
oRecurring (including, but not limited to herpes simplex, herpes zoster, recurring 
cellulit is, chronic osteomyelit is) 
Subjects with recurrent nonserious infect ions such as cellulit is and 
unco mplicated orolabial and/or genital herpes may be enro lled at the discret ion 
of the invest igator when deemed not to place subjects at an increased risk of 
complicat ions
24.Have any of the fo llowing:
Hum an immunodeficiency virus (HIV) infect ion
Current infect ion with hepatitis B virus (HBV) (i.e., posit ive for hepatit is B surface 
antigen and/or polymerase chain react ion [PCR ]posit ive for HBV DNA )
Current infect ion with hepatitis C virus (HCV) (i.e., posit ive for HCV RNA) 
Active tuberculosis (TB)
25.Have or have had latent TB infect ion (LTBI) that has not been treated with a complete 
course of appropriate therapy  as defined by the World Health Organizat ion (WHO) 
and/or the United States Centers for Disease Control and Prevent ion (CDC), unless such 
treatm ent is underway, as per Section 8.2.6 .
26. C urrent or recent acute active infection, or fever of 100.5°F (38°C) or above, at screening 
or baseline . For at least 30 days prior to screening, p articipants must have no symptoms 
and/or si gns of confirmed or suspected infect ion, and must have completed any 
appropriate anti -infective treatment
27.Have estimated glo merular filtrat ion rate from serum creatinine using the Modification o f 
Diet in Renal  Disease m ethod of <60 mL/minute   
28.Participants having contraindicat ions to MRI (for example, claustrophobia, pacemakers, 
aneurysm clips, intraocular metallic fragments) or IV gadolinium diethylenetriamine 
penta -acetic acid ( [Gd-DTPA ];moderate or severe renal insufficie ncy, prior allergic 
reacti on to gadolinium -containing contrast m edia)
29.Are women who are currently pregnant or breastfeeding, or who intend to become 
pregnant or to breastfeed at any  time during the study  or wi thin 20 weeks after receiving 
the last dose of study  drug.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
30Prior/Concomitant Therapy
30.Current ly receiving or have received any of the fo llowing therapi es within 28 days pri or 
to the screening MRI :
MTX, hy droxychl oroquine, sulfasalazine, or leflunomide at an unstable dose
(defined as a change in prescript ion).
This also includes a planned dose change during the study  (including init iation or 
discontinuat ion)
Cyclophosphamide, azathi oprine, cy closporine, gold, mycopheno late mofetil, 
Prosorba column, or Tacrolimus
Oral Janus kinase inhibitor (e.g., tofacit inib, baricit inib)
Parenteral  corti costeroi ds, incl uding initiation of planned treatm ent during the study
Note: A single intra -articular corticosteroid inject ion is permitted within 28 days 
prior to the screening MRI if no more than 40 mg triamcino lone (or equivalent) is 
administered and no further injections are pl anned during the study . The treated joint 
shoul d be excluded from  any j oint-specific evaluatio ns during the study .
A chronic narcotic drug at an unstable dose . This also includes planned increase/new 
prescri ption during the study
31. H ave received any  of the f ollowing bio logic immunosuppressive therapies under the 
defined condit ions or pl an any such treatm ents during the study  (other bi ologic agents 
may be allowed afte r discussio n with the sponsor and upon agreement in writing):
Etanercept, adalimumab, anakinra , infliximab, certolizumab pego l, golimumab, 
abatacept, or tocilizumab within 8 weeks prior to screening MRI
B-cell–deplet ing agents (such as rituximab) or other cell-deplet ing biologics (e . g., 
anti
-CD3 ant ibody ) within 12 m onths pri or to screening MRI
32. H ave failed more than 2 bDMARDs or tsDMARDs (e.g. excluded if have failed 
2bDMARDs and 1 tsDMARD)
33.Have previously co mpleted a clinical trial invest igating any  other mole cule targeting 
PD-1 or have previously discont inued fro m this study  after receiving LY3462817
Prior/Concurrent Clinical Study Experience
34.Are cu rrently enrolled in any other clinical trial invo lving a study  interventi onor any  
other ty pe of medical res earch judged not to be scient ifically or medically co mpat ible 
with this study
35.Have part icipated, wi thin the last 30 days, in a clinical trial invo lving study  intervent ion.
If the previous study  interventi onhas a l ong half -life, 3 months or 5 half -lives (w hichever 
is longer) should have passed prior to screening
36.Have p reviously com pleted or withdrawn fro m this study
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
31Other Exclusions
37.Are in vestigator site personnel directly affiliated wit h this study  and/or thei r immediate 
families. Immediate family  is defined as a spouse, parent, child, or sibling, whether 
biological  or legally  adopted.
38.AreLilly  empl oyees or em ployees of third -party organizat ions involved with the study  
that require exclusio n of their emplo yees
39.Arenot willing to receive IV injections
40.Are uns uitable for inclusio n in the study, in the opinio n of the investigator or sponsor, for 
any reason that may co mpromise the participant ’s safet y or confound data interpretation
5.3. Lifestyle Considerations
All study  parti cipants shoul d be instructed not t
o donate bl ood or bl ood products during the study  
or for 6 months after the last dose of the study  intervent ion.
Reproductive and Contraceptive guidance is provided in Section 10.4, Appendix 4.
5.4. Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequently enrolled in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure partici pants to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries fro m regulatory  
author ities. Minimal informat ion includes demography, screen failure details, eligibilit y criteria, 
and any  SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) maybe 
rescreened only once for failure due to any  of the f ollowing criteria: 2, 8, 21, 22, 23, 26, 34, or 
35. Individuals who failed criterion 25 can be rescreened once if appropriate treatment for LTBI 
is underway. Rescreened participants should be assigned a new participant number. Each time 
rescreening is performed, the individual must sign a new ICF.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
326. Study Intervention
Study  intervent ion is defined as any invest igational intervent ion(s), m arketed product(s), 
placebo, or m edical device(s) intended to be administered to/used by  a study  parti cipant 
according to the study  protocol .
6.1. Study Intervention(s) Administered
Study interventions
Each participant will receive mult iple IV infusio ns of placebo ,LY3462817 300 mg,or 
LY3462817 700mg.
Intervention Name Placebo LY3462817 LY3462817
Dose Formulation 0.9% sodium chloride 
solutionSolution Solution
Unit Dose Strengths - 50 mg/mL in a 3- mL vial
Dosage Level(s)
(mg)Not applicable 300 700
Use Placebo Experimental
IMP and NIMP IMP IMP
Sourcing Commercially available 
0.9% sodium chloride 
solution sourced centrally by 
LillyFrom Lilly
Packaging and 
LabelingCommercially available 
0.9% sodium chloride 
solutionStudy intervention will be provided in glass vials and will 
be labeled as required per country requirement
Abbreviation s: IMP = Investigati onal Medicinal Product; NIMP = Non investigational Medicinal Product.
Study  intervent ionwill be prepared by  an unblinded pharm acy staff or pharm acist who i s not 
involved in any other study -related procedures.
The study  intervent ion is planned to be administered as a nIV infusio n. 
The infusio n rate m ay be reduced as deemed necessary  if aninfusio n react ion is observed 
(Secti on8.3.6 ). Participants will be monitored for signs and symptoms of infusio n react ion:
during the infusion, and 
for at least 1 hour after complet ion of the infusio n. 
Infusio n informat ion may be found in the pharmacy  binder .
Resusci tation equipment, em ergency drugs, and appropriately trained medical staff must be 
available during the infusio n and for at least 1 hour after the complet ion of the infusio n.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
336.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate storage conditio ns have been maintained 
during transit for all study  intervent ion received and any  discrepancies are reported and resolved 
before use of the study  interventi on.
Only participants enro lled in the study  may receive study  intervent ion and only authorized study 
staff or desi gnee may supply  or administer study  intervent ion. All study  interventi on must be 
stored in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage condit ions wit h access limited t o the invest igator and 
authori zed study  staff or desi gnee .
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance (i .e., 
recei pt,reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  interventi ons are 
provi ded in the pharmacy manual .
6.3. Measures to Minimize Bias: Randomization and Blinding
To preserve the blinding of the study , a minimum number of Lilly  personnel  who are not di rectly 
involved with invest igational sites will see the randomizat ion table and treatment assignments 
before the study  is com plete.
Joint, disease activity, and safety assessments 
Joint Assessor
To prevent potential biasdue to observed efficacy  or laboratory  changes, a “dual assessor” 
approach will be used to evaluate efficacy and safety . The Joint Assessor (or designee) should be 
a rheumatologist or skilled arthrit is assessor. The Joint Assessor will be responsible for 
completing the jo int counts. To ensure consistent joint evaluation throughout the trial, individual 
participants shoul d be eval uated by  the same Joint Assessor for all study  visits. The Joint 
Assessor must not access or discuss with the participant the pati ent-reported assessments, 
Physician’s Global Assessment of Disease Activit y (PhGADA_VAS), and safet y assessments.
Safety Assessor
The Safet y Assessor (or designee) sh ould be a rheum atologist (or m edically qualified physician) 
and will have access to both safet y and efficacy data. The Safet y Assessor may be the principal 
investigator. The Safet y Assessor will be responsible for completing the PhGADA_VAS. To 
ensure consi stent PhGADA_VAS throughout the trial, the instrument should be evaluated by the 
same physician at all study  visit s. The Safet y Assessor will have access to source documents, 
laboratory  resul ts, and el ectroni c case report forms (eCRFs) and will be responsi ble for making 
treatm ent deci sions based on a participant’s clinical response and laboratory  parameters.
Method of treatment assignment
Assignment to treatment groups will be determined by a co mputer -generated random sequence 
using an interactive web -respo nse system (IWRS).
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
34Parti cipants will be stratified by  prior use of csDMARD only or by tsDMARD/ bDMARDs use 
(yes versus no).
Emergency unblinding
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a participant’s treatm ent assi gnment i s warranted. Participant safety must always be the first 
consideration in making such a determinat ion. If a participant ’s treatment assignment is 
unblinded, the sponsor must be notified immediately.
Emergency  unblinding for AEs m ay be perform ed through the IWRS. This opti on m ay be used 
ONLY if the participant’s well-being requires knowledge o fthe participant’s treatment 
assignment. All calls result ing in an unblinding event are recorded and reported by  the IWRS .
6.4. Study In tervention Compliance
Study  intervent ion will be administered under medical supervisio n by the invest igator or 
desig nee. The date and time o f each dose administered will be recorded in the source documents 
and in the case report form ( CRF ). The dose of stu dy intervent ion and study  parti cipant 
ident ificat ion will be confirmed prior to the time of dosing.
6.5. Concomitant Therapy
Parti cipants will be instructed to consult the invest igator or other appropriate study personnel at 
the site before taking any new medicat ions or supplements during the study .
Addit ional drugs are to be avo ided during the study unless required to treat an AE or for the 
treatm ent of an ongoing medical condit ion. Invest igators should fo llow local guidelines for the 
management of lipid disorders. If the need for other concomitant medicat ions arises, 
discontinuat ion of the participant fro m study  intervent ion or the study  will be at the di screti on of  
the invest igator in consultat ion with sponsor (or desi gnee).
All medicati ons, whether prescript ion or over -the-counter, used at screening and/or during the 
study  must be docum ented in the eCRF with start and stop dates.
6.5.1. Permitted Rheumatoid Arthritis Concomitant Therapy
Treatment with the following conco mitant m edicati ons for RA during the study  arepermitted as 
outlined below and in the inclusio n/exclusion criteria. This applies to all part icipants during 
Period 1 and any  participant that remain son LY3462817 during Period 2.
Concomitant therapy Permitted Not permitted
Methotrexate ( MTX) If parenteral, up to 20 mg/week
If oral, up to 25 mg/week
Subjects on MTX should receive supplementation 
with folic acid according to local standard of care
Hydroxychloroquine up to 400 mg/day
Oral sulfasalazine up to 3000 mg/day
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
35Concomitant therapy Permitted Not permitted
Leflunomide up to 20 mg/day
Nonsteroidal anti -
inflammatory drugs 
(NSAIDs )Permitted during the Period 1 only if the participant 
was on a stable dose for at least 7 days before 
planned randomization. Increase of NSAID dose and/or 
introduction of new NSAIDs are 
not permitted during the Period 1 
or in participants receiving
LY3462817 in Period 2
Analgesics Dose reductions and/or termination of analgesics 
are permitted at any time.
Corticosteroids Prednisone (or equivalent) at doses up to 10 mg per 
day is allowed during this study but must be 
maintained at stable levels from ≥4 week sprior to 
the screening magnetic resonance imaging ( MRI)
through Period 1 or in participants receiving 
LY3462817 in Peri od 2.
Topical, intranasal, intraocular, and inhaled 
corticosteroids are permitted.
Directions for use of intra-articular 
glucocorticoids :
If an unforeseen intra -articular glucocorticoid 
injection is required during the study, it will be 
noted as a protocol deviation.
Any joints that had been injected with intra -articular 
corticosteroids within 42 days prio r to the screening 
MRI will be censored from the clinician -
administered Tender Joint Counts (TJCs) and 
Swollen Joint Counts (SJCs) (68/66) for the 
duration of the study.Participants who were not 
previously on prednisone (or 
equivalent) prior to 
randomization should not initiat e 
corticosteroid therapy during the 
study during Period 1 or in 
participants receiving 
LY3462817 in Period 2 , 
Participant s should not receive 
other systemic corticosteroids 
during the study including 
intra-muscular or intra -articular 
corticosteroids during Period 1 or 
in participants receiving
LY3462817 in Period 2. 
Folic acid Local standard of care should be followed for 
concomitant administration of folic acid.
6.5.2. Prohibited Concomitant Therapy
Live vaccinat ions are not allowed up to 3 months prio r to screening or at any  time during the 
study . Live herpes zoster vaccinat ion is not permitted within 30 days of planned rando mizat ion 
or at any  time during the study .
Nonlive seasonal vaccinat ions and/or emergency vaccination, such as rabies or tetanus 
vaccinations, are allowed .
6.5.3. Standard of Care Therapy after Week 14 
All placebo patients should begin SOC therapy  at Week 14 at the invest igator ’s discretion. 
Parti cipants randomized to LY3462817 at baseline and not achieving low disease act ivity 
(CDAI ≤10) at Week 14 will no l onger receive study  drug infusi ons and shoul d receive SOC 
therapy  at the invest igator’s discretion.    
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
36Parti cipants who achieve l ow di sease act ivity at Week 14, and maintain treatm entwith 
LY3462817 during Period 2, can be switched to SOC prior to Week 24 if the participant stops 
receiving clinical benefit. Name(s)and dosage regimen (s) must be recorded for the SOC therapy .
Standard of care medications will not be supplied by the sponsor.
6.6. Dose Modification
Dose m odificat ions during the treatm ent peri od will  not be allowed.
6.7. Intervention after the End of the Study
No continued access is planned after complet ion of this study , as addi tional efficacy woul d be 
needed to demonstrate continued access criteria.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
377. Discontinuation of Study Interven tion and Participant 
Discontinuation/Withdrawal
The sect ions below describe reasons for a participant’s
temporary  or perm anent discont inuat ion of study  intervent ion (Secti on 7.1), or
discontinuat ion (wi thdrawal) from  the study  (Section 7.2).
Discontinuati on of  specific sites or of the trial as a who le are handled as part of regulatory, 
ethical, and trial oversight considerat ions in Sect ion10.1, Appendix 1.
7.1. Discontinuation of Study Intervention
Study  intervent ion may be temporarily  withheld or permanently discont inued during the study .
Parti cipants who perm anent ly discont inue study  intervent ion early will undergo early terminat ion 
procedures, which include an early terminat ion visit anda posttreatm ent follow-up visit (V801)
as described in the SoA (Section 1.3).
The invest igator will co mplete any  AE reporting and fo llow-up (Secti on8.3).
7.1.1. Criteria for Temporary Interruption (Withholding ) of Study Intervention
Study  treatm ent may  be tem porarily  discontinued if the partici pant requires surgery. 
Administrati on of  the study  interventi on may  be restarted only  after adequate wound healing.  
This and other situations that may merit temporary discont inuat ion of the study  interventi on 
shoul d be discussed wit h the sponsor. The invest igator shoul d consul t with the Medical Monitor   
and then determine when it is appropriate to recommence study  treatment.  
7.1.1.1. Infection -related Criteria for Temporary Withholding of Study Intervention
Study intervent ion will be temporarily wit hheld if any of the fo llowing infect ion-related cri teria 
occur during the study :
1.Serious or opportunist ic infect ions, as defined i n Exclusi on Cri teria (Secti on 5.2). Study  
intervent ion canbe withheld unt il resolut ion of all acute clinical signs and symptoms, and 
completion of all appropriate anti -infective treatment (exception for LTBI, noted below) . The 
investigator should consult with the Medical Monitor and thendetermine when it is 
appropriate to recommence study  treatm ent. 
2.If a participant is diagnosed with LTBI during the study and is treated for LTBI as fo llows: 
a)Study  intervent ion is temporarily held for at least the first 4 weeks of LTBI treatment.
b)If there is no evidence of hepatotoxicit y (ALT/AST m ust remain ≤2 times ULN) or other 
treatm ent intol erance a fter receiving at least 4 weeks of appropriate LTBI therapy  (as per 
WHO and/or CDC guidelines), then study  interventi on m ay be resumed. 
c)The participant must com plete appropr iate LTBI therapy during the course of the study  to 
remain eligible to continue to receive study  intervent ion.
3.HBV DNA results reported as posit ive, or as detecting HBV DNA, but HBV DNA is belo w 
the level o f quantificat ion. The Medical Monitor should be c ontacted regardin g study  status 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
38of the participant . Hepati tis B virus DNA testing shoul dbe repeated as soon as possible .If 
HBV DNA is confirmed posit ive, then study  intervent ion shoul d be discont inued.
7.1.2. Criteria for Permanent Discontinuation of Study Intervention
In rare instances, it may be necessary  for a parti cipant to perm anent ly discont inue (definit ive 
discontinuat ion) study  intervent ion. If study  intervent ion is definit ively  discontinued, the 
participant willbe encouraged to remain in the study . See the SoA for data to be collected at the 
time of discont inuat ion of study  intervent ion and follow -up and for any  further evaluat ions that 
need to be completed .
Perm anent discont inuat ion of study  intervent ion shoul d occur if the scenariosdescribed occu r 
during the study .
Participant decision
The parti cipant requests to discontinue the study  intervent ion.
Investigator decision
The invest igator decides that the participant should be discontinued from the 
study  interventi on.
Pregnancy
The parti cipant beco mes pregnant during the study (see Section 8.3.5 and 
Secti on10.4, Appendix 4).
Safety considerations
The parti cipant:
Has a malignancy (except for successfully treated basal or squamous cell skin carcino ma)
Answered "yes" to Question 4 or Question 5 on the "Suicidal Ideat ion" porti on of  the 
C
-SSRS
Answered "yes" to any  of the sui cide-related behaviors on the Suicidal Behavior portion
of the C -SSRS
A psychiatrist or appropriately trained professio nal may  assist in the decision to 
discontinue the participant.
Is diagnosed with LTBI during the study  and are not a candidate for treatment as 
described in Section 7.1.1.1 ,  or
Has a serious or opportuni stic infect ion that in the opinio n of the invest igator merits the 
study  interventi onbeing discont inued. Such in fections may include, but are not limit ed 
to:
oHIV/acquired immune deficiency syndrome (AIDS) infect ion
oactive TB infect ion or untreated LTBI (see Sections 7.1.1 and 8.2.6 )
oHCV RNA posit ive (Sect ion8.2.8 )
oHBV DNA posit ive (Section 8.2.7 ).
The participant shoul dbe referred to, evaluated a nd managed by a specialist physician with 
expert ise in evaluat ion and management of viral hepatit is prior to discont inuat ion of any  
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
39immuno modulatory  and/or imm unosuppressive therapy ,including study intervent ion. Timing of 
discontinuat ion from study  intervention relative to the init iation of any  antiviral treatment for 
hepat itis is to be based on the recommendat ion of the consult ing specialist physician, in 
conjunction with the invest igator, and aligned wit h medical guidelines and standard of care.
Hepatic event or liver test abnormality
Parti cipants who are di scont inued fro m intervent ion due to a hepatic event or liver test 
abnorm ality should have addi tional hepatic safet y data collected via eCRF. The investigator 
shoul d consul t with the m edical mo nitor todetermine if d iscont inuat ion of the intervent ionfor 
abnorm al liver tests should be considered ifa partici pant m eets one of the secondi tions (see 
Secti on10.7, Appendix 8):
ALT or AST >8 times ULN
ALT or AST >5 times ULN for more than 2 weeks
ALT or AST >3 times ULN and TBL >2 times ULN or international normalized 
ratio (INR) >1.5 
ALT or AST >3 times ULN with the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
ALP >3 times ULN
ALP >2.5 times ULN and TBL >2 times ULN, or 
ALP >2.5 times ULN with the appearance of fat igue, nausea, vo miting, right 
quadrant pain or tenderness, f
ever, rash, and/or eosinophilia (>5%)
See the SoA for data to be collected at the time of intervent ion discontinuation and fo llow-up and 
for any  further evaluat ions that need to be completed.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study :
●at any  time at his/her own request 
●at the request of his/her designee (for example, legal guardian)
●at the discretion of the invest igator for safet y, behavi oral, com pliance, or 
administrative reasons
●if the parti cipant beco mes pregnant during the study
●if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study
●if the participant , for any  reason, requi res treatm ent wi th another therapeuti c agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
Discontinua tion is expected to be uncommo n.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
40At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as shown in the SoA. See SoA (Section 1.3)for data to be collected at the time of 
study  discont inuat ion and fo llow-up and for any  further eval uations that need to be completed.
The parti cipant will be permanently discont inued from the study intervent ion.
If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay retain 
and cont inue to use any data collected before such a withdrawal o f consent .If a participant
withdraws fro m the study , he/she may  request destructi on of  any sam ples taken and not tested ,
and the invest igator must document this in the site study records .
7.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ifya partici pant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  treatm ent unl ess 
there are extenuating circumstances that make it medically necessary for the participant to 
continue on study  treatm ent.Additional country -specific requirements for discont inuat ion of 
inadvertent ly enro lled participants is provided in Secti on10.10 ,Appendix 10.
The invest igator should consult with the Medical Monitor ,then determine if it is medically 
appropriate to continue . The invest igator must obtain documented approval fro m the Medical 
Moni torto allow the inadvertent ly enro lled participant to continue in the study with or without 
treatm ent wi th invest igational product.
Safety follow up i s as outlined in :
Secti on 1.3(SoA)
Secti on 8.2(Safet y Assessments), and
Secti on8.3(Adverse Events and Serious Adverse Events).
7.3. Lost to Follow up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.Site personnel are expected to 
make diligent attempts to contact participants who fail to return for a scheduled visit or were 
otherwi se unable to be fo llowed up by the site.
Site personnel, or an independent t hird party , will  attem pt to collect the vital status of the 
participant wi thin legal  and ethical boundaries for all participants randomized, including those 
who did not get study interventi on.Public sources may be searche d for vital status inform ation.
If vital status i s determined to be deceased , this will  be docum ented and the parti cipant will not 
be considered lost to follow -up.Sponsor personnel will not be invo lved in any attempts to collect 
vital status inform ation.
Discontinuati on of  specific sit es or of the study  as a who le are handled as part of Section 10.1, 
Appendix 1.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
418. Study Assessments and Procedures
Study  procedures and their timing are summari zed in the SoA. Protocol waiver s or exem ptions 
are not allowed.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon occurrence or 
awareness to determine if the participant should cont inue or discont inue study  intervent ion.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al participant s
meet all eligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participant s screened and to confirm eligibilit y or record reasons for sc reening failure, as 
applicable.
Moni toring of blinded safet y data will cont inue throughout the study and will b e conducted by  
blinded study  team  members. Details o f the blinded safet y reviews, including the frequency  and 
approximate timing, are specified in the trial level safet y review pl an.
8.1. Efficacy Assessments
All patient -reported and clinician -reported efficacy assessments will be captured on an electronic 
tablet collected at site visit s.
8.1.1. Disease Activity Score –High -Sensitivity C -Reactive Protein (DAS28 -hsCRP)
The DAS28 -hsCRP measures disease act ivity in 28joints using a co mposite numeric score of the 
following variables (Vander Cruyssen et al. 2005): 
TJC
(see Section 8.1.4 )
SJC(see Section 8.1.4 )
high sensit ivity C-reactive protein ( hsCRP ), and
Patient’s Gl obal Assessment of Di sease Act ivity (PaGADA_VAS ; see Secti on8.1.7 ).
The 28 joints examined and assessed as tender or not tender for TJC and as swo llen or not 
swollen for SJC include 14 joints on each side of the participant ’s body  (Sm olen et al. 1995): 
the 2 shoulders
the 2elbows
the 2wrists
the 10 m etacarpophal angeal  joints
the 2interphalangeal jo ints of the thumb
the 8proximal interphalangeal jo ints, and
the 2knees.
8.1.2. Disease Activity Score –Erythrocyte Sedimentation Rate (DAS28 -ESR)
The DAS28 -ESR m easures disease act ivity in 28joints using a composite numeric score of the 
following variables (Vander Cruyssen et al. 2005): 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
42TJC (Secti on8.1.4 )
SJC(Secti on8.1.4 )
Erythrocyte sedimentati on rate ( ESR), and
PaGADA_VAS (Secti on8.1.7 ).
For descript ion of the 28 jo ints to be examined, see Section 8.1.1 .
The DAS28 -ESR remissi on is defined as DAS28 -ESR <2.6, and DAS28 -ESR LDA is defined as 
DAS28 -ESR ≤3.2.
8.1.3. American College of Rheumatology Criteria ( ACR20, ACR50, and ACR70 )
The ACR20 is defined as at least 20% improvement in the ACR core set values. Similarly, 
ACR50 and ACR70 are defined as at least 50% and70% improvement in the ACR core set 
values .
This is defined as :
an improvement of at least 20%, 50%, or 70% in the TJC and SJC (68/66 ; Section 8.1.4 )
AND
an improvement of at least 20%, 50%, or 70% in at least 3 of the fo llowing 
5assessments:
1.Patient’s Global Assessment of Arthri tis Pain ( visual analog scale [VAS ]; 
Secti on8.1.6 )
2. Pa GADA_VAS (Secti on8.1.7 )
3.PhGADA_VAS (Secti on8.1.5 )
4.Patient’s Assessment of Physical Funct ion as measured by  the Heal th Assessment 
Quest ionnaire -Disabilit y Index (HAQ -DI; Section8.1.8 )
5.Acute phase rea ctant as m easured by hsCRP
8.1.4. Tender Joint Count and Swollen Joint Count
The j oint exam will be performed by the Jo int Assessor and reviewed by  the Safety  Assessor 
(Secti on6.3).
8.1.5. Physician’s Global Assessment of Disease Activity (PhGADA _VAS)
The PhGADA_VAS is used a s a com ponent of ACR (Secti on8.1.3 )
 as well as a separate 
efficacy  assessment.
The PhGADA_VAS is a single item that asks the physician to assess the patient’s current disease 
activit y on a 0 -to 100 -mm VAS, with anchors of 0 =“no disease act ivity” and 100 =“extremely 
active disease.”
8.1.6. Patient’s Global Assessment of Arthritis Pain (Visual Analog Scale )
ThePatient’s Global Assessment of Arthri tis Pain (VAS )isused a s a com ponent of ACR 
(Secti on 8.1.3 ) as well as a separate efficacy assessment.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
43The Patient’s Global Assessment of Arthri tis Pain (VAS )is a single item that asks the patient to 
rate the current severit y of their pain in relat ion to thei r RA on a 0 -to 100 -mm VAS, with 
anchors of “no pain” and “worst possible pain .”
8.1.7. Patient’s Global Assessment of Disease Activity (P aGADA _VAS)
The PaGADA_VAS i s used a s a com ponent of ACR (Secti on 8.1.3 ) as well as a separate 
efficacy  assessment.
The P aGADA_VAS i s a single i tem that asks the pati ents to indicate how they  feel thei r RA is 
today  on a 0 -to 100 -mm VAS, with anchors of 0 =“very well” and 100 =“very poor .”
8.1.8. Health Assessment Questionnaire -Disability Index (HAQ -DI)
TheHAQ- DI isused as a component of ACR (Section 8.1.3 ) as well as a separate efficacy 
assessment .
The HAQ -DI is a patient -reported questionnaire that is commo nly used in RA to measure 
disease -associ ated di sabili ty (assessment of physical funct ion). It consists of 24 questions 
referring to 8 domains (Fries et al. 1980, 1982; Ramey et al. 1996): 
1.dressing/grooming
2.arising
3.eating
4.walking
5.hygiene
6.reach
7.grip,and
8.activit ies. 
Participants use a scale fro m 0 to 3 to score difficult y when performing these and other daily  
activit ies over the past week (0 = without any difficult y, 1 = wi th som e difficul ty, 2 = wi th much 
difficult y, and 3 =unable to do). The reported use of special aids or devices and/or the need for 
assistance of another person to perform these act ivities is also assessed. Higher scores indicate 
more limi tations in physical funct ion. The scores for each of the funct ional do mains will be 
averaged to calculate the funct ional disabilit y index.
8.1.9. Simplified Disease Activity Index (SDAI)
The SDAI is a tool for meas urement of di sease act ivity in RA that integrates measures of 
physical examinat ion, acute phase response, patient self -assessment, and evaluator assessment. 
The SDAI is calculated by  adding together scores from the following assessments:
number of swo llen joints (0 to 28)
number of tender jo ints (0 to 28)
CRPin mg/dL (0.1 to 10.0)
PaGADA_VAS (0 to 100 mm), and 
PhGADA_VAS (0 to 100 mm) (Aletaha and Smo len 2005).
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
44Disease remissio n according to ACR/EULAR index -based definit ion of remission is de fined as 
an SDAI score of ≤3.3 (Felson et al . 2011) .Low disease act ivity is defined as an SDAI score of 
≤11.
8.1.10. Clinical Disease Activity Index (CDAI)
The CDAI i s similar to the SDAI, but it allows for immediate scoring because it does not use a 
laboratory  resul t. The C DAI i s calculated by  adding together scores from the following 
assessments:
number of swo llen jo ints (0 to 28)
number of tender jo ints (0 to 28)
PaGADA_ VAS (0 to 100 mm), and 
PhGADA_ VAS (0 to 100 mm) (Aletaha and Smo len 2005).
Remissio n is defined as a CDAI score of ≤2.8 (Felson et al. 2011) . Low disease activit yis 
defined as a CDAI score of ≤10.
8.1.11. Medical Outcomes Study 36- Item Short Form Health Survey
The Medical Outcom es Study  36-Item Short Form  Heal th Survey ( SF-36v2) Acute m easure is a 
subjective, generic, healt h
-related quali ty of life instrum ent that i s pat ient-reported and consists 
of 36 questi ons covering 8 healt h domains:
physical funct ioning
bodily  pain
role limi tations due to phy sical probl ems
role limi tations due to em otional problems
general healt h perceptions
mental  health
social function, and
vitality.
Each domain is scored by  summing the individual items and transforming the scores into a 0 to 
100 scale wit h higher scores indicat ing better health status or fun ctioning. 
In addit ion, 2 summary  scores, the physical component score and the mental component score, 
will be evaluated based on the 8 SF -36v2 Acute domains (Brazier et al. 1992; Ware and 
Sherbourne 1992).
8.1.12. MRI Imaging and Synovitis Score
Magnet ic resonance imaging is a more sensit ive, noninvasive imaging technique that can provide 
cross -sectional images in any plane allo wing for simultaneous examinat ion of all the co mponents 
of the diarthrodi aljoint (including soft ti ssues, articul ar cartilage, and bone) without the need for 
ionizing radiat ion (McQueen and Da lbeth 2009). Specifically , both inflammatory  changes (as 
represented by  synovitis and osteitis) and structural changes (as represented by erosi on and j oint 
space narrowing) are characterist ic features of RA that may  be detected in patients by MRI 
imaging (Klarlund et al. 2000). 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
45Magnet ic resonance imaging scans wi llbe conducted on hand/wrist determined by the 
investigator at the site, durin g screening and at the Week 12 visit. Screening scans will be 
evaluated to determine the presence of syno vitis for study  eligibility. Screening and Week 12 
scans will be read and scored in pairs for each subject by  2assessors at a central vendor, blinded 
to each subject’s treatment and t he temporal order of the scans. A detailed charter from the 
central  reading laboratory  will outline the MRI procedures including image acquisit ion, image 
analysis ,and data transfer .
Synovit is, osteit is, bone erosion, and j oint space narrowing scores are pl anned to be determined 
using the OMERACT RAMRIS sy stem  for synoviti s, ostei tis, and bone erosion ( Østergaard et al. 
2017).
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA.
8.2.1. Physical Examinations
A co mplete physical examinat ion will be performed at the screening visit according to the SoA 
(Secti on1.3). This examinat ion excludes pelvic, rectal , and breast examinat ions unless clinically 
indicated.   
A symptom directed physical examinat ion will be performed at other visits, as specified in the 
SoA and as clinically indicated. A complete physical examinat ion may be repeated at the 
investigator’s di scret ion at any  time a participant presents with physical co mplaints.
Invest igators should pay special attention to clinical signs related to previous serious illnesses.
8.2.2. Vital Signs
For each participant , vital signs m easurements shoul d be conducted according to the SoA
(Secti on1.3). Vital signs include body  temperature, bl ood pressure, and pulse r ate(PR) .
Parti cipants shoul d be seated and relaxed wit h both feet on the floor for at least 5 minutes before 
measurements are taken. Blood pressure and pulse should be measured using either automated or 
manual equipment. If measurements are machine averag ed, the average blood pressure reading 
shoul d be recorded on the eCRF. 
Measurements should be taken before any  scheduled bl ood draws. 
Addit ional vital signs may be measured at the discretion of the invest igator.
8.2.3. Electrocardiograms
Single 12-lead ECG will be obtained as outlined in the SoA (Section 1.3)  using an ECG machine 
that autom atically  calculates the heart rate and measures PR, and QRS andQT intervals. 
8.2.4. Clinical Safety Laboratory Assessments
See Secti on10.2, Appendix 2 for the list of clinical laboratory  tests to be performed and to the 
SoA for the timing and frequency.
The invest igator must review the laboratory report, documen t this review, and record any  
clinically relevant changes occurring during the study  in the AE section of the CRF. The 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
46laboratory  reports m ust be filed wit h the source documents. Clinically significant abnormal 
laboratory  findings are those that are not as sociated with the underlying disease, unless judged 
by the investigator to be more severe than expected for the participant's condit ion.
All laboratory  tests wi th values considered clinically  significantly abnorm al during parti cipat ion 
in the study  or wi thinapproximately  30 days after the last dose of study  intervent ion shoul d be 
repeated until the values return to normal or baseline or are no longer considered clinically 
significant by  the invest igator or medical mo nitor.
If such values do not return to n ormal/baseline wit hin a peri od of  time judged reasonable by  the 
investigator, the etiology  shoul d be i dentified and the sponsor notified.
All protocol -requi red laboratory  assessments, as defined in Section10.2, Appendix 2, must be 
conducted in accordance with the laboratory  manual  and the SoA.
If laboratory  values fro m nonprotocol specified laboratory  assessments perform ed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are considered 
clinically significant by  the investi gator (e .g., SAE or AE or dose modificat ion), then these 
woul d be reported in the AE sect ion ofthe CRF.
8.2.5. Suicidal Ideation and Behavior Risk Monit oring
Parti cipants being treated with the study  intervent ion should be monitored appropriately and 
observed for suicidal ideat ion and behavior or any other unusual changes in behavior, especially 
at the beginning and end o f the course of treatment, or at the time of dose ch anges, ei ther 
increases or decreases. Considerat ion shoul d be given to di scontinuing the study  medicat ion in 
participants who experience signs of suicidal ideat ion or behavior, fo llowing a ri sk assessment.  
Families and caregivers of participants being tr eated with the study  intervent ion shoul d be 
alerted about the need to monitor participants for the emergence of unusual changes in behavior, 
as well as the emergence of suicidal ideat ion and behavior and to report such symptoms 
immediately  to the study  investigator. 
Baseline assessment of suicidal ideation and behavior and treatment emergent suicidal ideation 
and behavior will be monitored during Study  KDAD using the C -SSRS.  
C-SSRS Self-Harm Supplement and Follow -Up form s
The C-SSRS is a scale that captures the occurrence, severit y, and frequency  of suicidal ideation 
and behavior during the assessm ent peri od via a questi onnai re.The scale was developed by the 
National Inst itute of Mental Health trial group (Treatment of Ado lescent Suicide Attempters 
study )for the purpose of being counterpart to the Columbia Classificat ion Algori thm of Suicide 
Assessment (C -CASA) categorizat ion of suicidal events.
Consistent with Food and Drug Administration (FDA) regulatory  guidance (FDA 2012), any  
occurrence of suicide -related thoughts and behavio rs will be assessed as indicated in the SoA 
(Secti on1.3).  
The Lilly Self -Harm  Supplement shoul d be com pleted every  time the C -SSRS is administered.
If, based on administration of the C -SSRS, i t is determined that suicide -related behaviors have 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
47occurred, then the Lilly Self -Harm  Follow-Up form will be used to collect additional inform ation 
to allow for a more complete assessment of these behaviors.
For thi s study , the C -SSRS i s adapted for the assessment of the ideat ion and behavior categories 
only. The Intensi ty of Ideati on and Lethalit y of Behavior sect ions are removed.
8.2.6. Tuberculosis Testing and Monitoring
Tuberculosis testing at screening Visit 1
Medical history  willdetermine the lifetime risk factors for TB infection, for TB progression, and 
for symptom s and/or si gns of  active TB .
A physical examinat ion will determine symptoms of active TB, including measurement of 
body temperature (Secti on8.2.2 ) and assessment of peripheral lymph nodes .
A chest x -ray(CXR) will be interpreted a nd reported by a radiologist or pulmo nologist, as 
specified in the SoA (Section 1.3). Participants do not need to have a CXR at screening if result s 
from a CXR wi thin 3months pri or to the study  are available.
All participants with no history  of LTBI or active TB, and no history  of posi tive Mantoux 
tuberculin skin test (TST) using purified p rotein derivat ive (PPD) or posit ive Mycobacterium 
tuberculosis interferon gamma release assay  (IGRA), m ust have eithera PPD TST or IGRA for 
M. tuberculosis .
PPD TST
An indurat ion of 5 or more millimeters is considered posit ive in:
HIV-infected persons
persons wi th a recent contact wi th a person wi th TB di sease
persons with fibrotic changes on chest radiograph consistent with prior TB
persons with organ transplants
persons who are immunosuppressed for other reasons (e.g., taking the equivalent of 
>15mg/da y of prednisone for 1 month or longer, taking TNF- α antagonists)
An indurat ion of 10 or more millimeters is considered positive in all other potential clinical trial 
participants.
Two-step testing (repeat TST from 1 to 3 weeks after the first TST) is reco mmended for certain 
participant groups, including: 
persons receiving immunosuppressant treatment
persons with a history  of temporally remote increased risk of TB infect ion
persons for whom  the fi rst test i s negat ive, as per local public health and/or professio nal 
medical societ y recommendat ions.
IGRA for M .tuberculosis
Ensure that specimen handling, transport, timing, and laboratory  procedures m eet all  
requi rements per package inse rt.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
48Diagnosed LTBI
Parti cipants diagnosed wi th LTBI are excluded (Section 5.2) unless they  are candidates for LTBI 
treatm ent, are treated for LTBI, and the following criteria are met:
After receiving at least 4 weeks of appropriate LTBI therapy (as per W HOand/or 
the CDC guidelines), there is no evidence o f hepatotoxicit y (ALT/AST m ust 
remain ≤2times ULN) ,or other treatm ent intol erance. 
The parti cipant m ust continue and com plete appropri ate LTBI therapy  in order to 
remain eligible to continue to receive study  intervent ion.
Monitoring during the study
At a minimum, each participant willhave the fo llowing docum ented at l east every  3 months:
Thorough history  to determine any  risk factors for TB infect ion and for TB 
progression, symptoms ,or signs of act ive TB, and
A thorough physical examinat ion that includes assessment for signs of act ive TB, 
including measurement of body  temperature and assessment of peripheral  lymph 
nodes.
8.2.7. Hepatitis B Testing and Monitoring
Initial testing for HBV infect ion includes hepat itis B surface ant igen ( HBsAg )and hepat itis B 
core anti body  (anti-HBc).
If… Then…
If HBsAg is positive the participant is excluded 
If HBsAg is negative and anti -HBc is negative the participant is not excluded
If HBsAg is negative and anti -HBc is positive further testing for HBV DNA is required
If the screening HBV DNA is positive the participant is excluded (see Section 5.2)
Parti cipants who are hepatit is B core antibody -positive and HBV DNA -negative (undetectable) 
at Vi sit 1 are not excl uded but will require HBV DNA mo nitoring every  3 months and at the 
participan t’s last visi t.
The fo llowing acti ons shoul d be taken in response to HBV DNA test results.
If… Then…
If a si ngle result is obtained with a value “below limit of 
quantitation ”the test should be repeated within approximately 
2weeks
If the repeat test result is “target not detected” monitoring may resume according to the study schedule
If the participant has 2 or more test results with a value 
“below limit of quantitation” during the studyHBV DNA testing should be performed approximately 
once per month for the remainder of the study and 
referral to a hepatologist is recommended
If a result is obtained with a v alue “above limit of 
quantitation ”at any  time  during the studythe participant will be permanently discontinued from 
the study  interventio n(see Section 7.1) and should be 
referred to a hepatology specialist immediately.
In selected cases, investigators may temporarily continue 
study intervention in accordance with current 
immunomodulator management in the setting of HBV 
DNA positivity. This option may be considered in 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
49If… Then…
consultation with the sponsor (or its designee) and after 
evaluation of individual participant’s risks and benefits.
8.2.8. Hepatitis C Testing and Monitoring
Initial testing for HCV infect ion includes testing for antibodies to HCV. 
If… Then…
If anti -HCV is positive HCV RNA testing should be performed   
If HCV RNA test is negative the participant is not excluded
If HCV RNA test is positive the participant is excluded (see Section 5.2)
Parti cipants who have had HCV infection and have been successfully  treated, defined as a 
sustained viro logic response (HCV RNA by  PCR negat ive for at least 24 weeks following 
treatm ent com pletion) are not excluded on the basis of HCV as long as HCV RNA test is 
negat ive at screening.
If HCV RNA is detected during the study , the study  drug will be perm anently discont inued 
(Secti on7.1), and the participant should receive appropriate follow -up medical  care.
8.3. Adverse Events and Serious Adverse Events
Adverse event s will be reported by  the parti cipant (or, when appropri ate, by  a caregiver, 
surrogate, or the participant's legally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or that 
caused the participant to discont inue the study  intervent ionor the study(see Sect ion7).
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All SAEs will be co llected fro m the signing of the ICF until participat ion in study  has ended .
All AEs will be co llected fro m the signing of the ICF until partici pation in study  has ended.
Adverse events that begin before the start of study  intervent ion but after signing of the ICF will 
be recorded on the AE CRF.
Although all AEs after signing the ICF are recorded by the site in the CRF/electronic dat a entry , 
SAE reporting to sponsor begins after the participant has signed the IC F and has received study  
drug. However, if an SAE occurs after signing the ICF, but prior to receiving the study  
intervent ion, it needs to be reported ONLY if it is considered reasonably  possibly  related to study  
procedures.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours, as indicated in Section 10.3,
 Appendix 3. The 
investigator will submit any  updated SAE data to the sponsor within 24 hours of it being 
available.
Invest igators are not obligated to actively seek AEs or SAEs after concl usionof the study  
participat ion. However, if the invest igator learns of any SAE, including a death, at any t ime after 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
50a participant has been discharged from the study , and he/she considers the event to be reasonably  
related to the study  intervent ion or study  participati on, the invest igator must prompt ly notify  the 
sponsor .
8.3.1.1. Adverse Event Monitoring with a Systematic Questionnaire
Nonl eading AE collect ion shoul d occur pri or to the collect ion of the C -SSRS.
If a suicide -related event i s discovered during the C-SSRS but was not captured during the 
nonleading AE collect ion, sites shoul d not change the AE form.
If an AE i s seri ous or l eads to discont inuat ion, it needs to be included on the AE form and the 
process for reporting SAEs is fo llowed.
8.3.2. Method of Detectin g AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Section10.3, Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about A E
occurrences .
8.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All SAEs and AEs of special interest (AESIs) (as defined in 
Secti on8.3.6 ), will be fo llowed unt il reso lution, stabilizat ion, the event is otherwise explained, 
or the participant is lost to follow -up (as defined in Sec tion7.3). Further informat ion on 
follow-up procedures is provi dedin Section 10.3, Appendix 3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towa rds the safet y of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, 
Institutional Review Boards (IRB)/Independent Ethics Committees 
(IEC) , and invest igators.
An invest igator who receives an invest igator safety report describing a SAE or other specific 
safet y informa tion (e.g., summary  or list ing of SAEs) from the sponsor will review and then file 
it along wi th the IBand will notify the IRB/IEC, if appropriate according to local requirements.
8.3.5. Pregnancy
Details o f all pregnancies in female participants and female part ners of male participants will be 
collected after the start of study  intervent ion and unt il8weeks after the l ast dose .
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
51If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy  and shoul d follow the procedures outlined in Section10.4, Appendix 4.
Abnorm al pregnancy outcom es (e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopi c pregnancy ) are considered SAEs.
8.3.6. Adverse Events of Special Interest
Adverse events of special interest for this study  include :
hypersensit ivity
infusio n site reactions
infect ions, and
malignancy.
Hypersensitivity
Many  drugs, but parti cularly bio logic agents, carry the risk of systemic hypersensit ivity 
reacti ons. If such a reaction occurs, addit ional data describing each symptom should be provided 
to the sponsor in the eCRF.  
Sites shoul d have appropri ately  trained medical staff and appropriate medical equipment 
available when study  parti cipants are receiving study  drug. It is recommended that participants 
who experience a systemic hypersensit ivity react ion be treated per national and internat ional 
guidelines.  
In the case of generalized urticaria or anaphylaxis, addit ional blood and urine samples should be 
collected as described in Secti on10.6,
 Appendix 6, Recommended Laboratory Test ing for 
Hypersensi tivity Events. Laboratory results are provided to the sponsor via the central 
laboratory .
Infusion Site Reactions
Symptom s of a l ocal infusi on site reacti on may  include ery thema, indurat ion, pain, pruritus, and 
edem a. If an infusio n site event is reported, the AE will be recorded, and addit ional data will be 
provi ded to the sponsor in the eCRF.  
Infections
Parti cipants will be m onitored f or symptoms and signs o f infect ionafter administrati on of  
LY3462817. More detailed informat ion may be found in the I B.
Opportunistic Infections
The sponsor will identify infect ions considered to be opportunistic based on the publication 
“Opportuni stic infections and bio logic therapi es in immune -mediated inflammatory  diseases: 
consensus recommendat ions for infect ion reporti ng during clinical trials and postmarketing 
surveillance” (Wint hrop et al . 2015).
Malignancy
Parti cipants will be m onitored f or symptoms and signs o f malignancy after administration of 
LY3462817. More detailed i nform ation may be found in the I B.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
528.3.7. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges deficiencies 
related to the identit y, qualit y, durabilit y, reliabilit y, safety, effect iveness ,or performance of a 
trial intervent ion.
Sponsor collects product complaints on investigational products used in clinical studies in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facili tate process and product 
improvements.
Parti cipants will be instruct ed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th theinvest igational product so that the situation can be assessed.
NOTE: A dverse event s/serious adverse event s that are associated with a product complaint will 
also fo llow the processes outlined in Section 8.3.3 and Section10.3, Appendix 3of the protocol .
8.3.7.1. Time Period for Detecting Product Complaints
Product complaints that resul t in an AEwill be detected, documented, and reported to the 
sponsor during all periods of the study  in wh ich the intervent ionis used.
If the inv estigator l earns of any product com plaint at any  time after a participant has been 
discharged from  the study , and such incident is considered reasonably related to a drug provided 
for the study , the invest igator will pro mptly notify the sponsor.
8.3.7.2. Prompt Reporting of Product Complaints to Sponsor
Product complaints will be reported to the sponsor within 24 hours after the invest igator beco mes 
aware of the complaint.
The Product Complaint Form will be sent to the sponsor by  the methoddesignated by  the 
sponsor .If the primary method is unavailable, the sponsor will designate an alternat ive method .
8.3.7.3. Follow -up of Product Complaints
Follow-up applies to all participants, i ncluding those who discont inue study  intervent ion.
The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the product complaint .
New or updated informat ion will be recorded on the originally co mpleted form wit h all changes 
signed and dated by  the invest igator and submitted to the sponsor .
8.4. Treatment of Overdose
The signs and symptoms of LY 3462817 overdose are not known. There is no known ant idote f or 
LY3462817 overdose.
In the event of an overdose, the invest igator should contact the Medical Monitor immediately.
Hem atology, chemistry , vital signs, and oxy gen saturati on shoul d be m onitored and supportive 
care should be provided as necessary.
Decisio ns regarding dose interruptions or modifications will be made by the invest igator in 
consultation wit h the Medical Monitor based on the clinical evaluat ion of the participant.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
538.5. Pharmacokinetics
At the visit s and t imes specified in the SoA (Secti on1.3),venous blood samples will be co llected 
to determine the serum concentrations of LY3462817.
Samples may  be drawn at addi tional time points during the study  if warranted and agreed upon 
betwe en both the investigator and sponsor. Instructio ns for the collection and handling o f blood 
samples will be provided by  the sponsor . The actual date and time of each sampling will be 
recorded.
LY3462817 concentration informat ion that m ay unblind the study  will not be reported to 
investigat ive sites or blinded personnel unt il the study has been unblinded.
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor. Concentrations of LY3462817 will be as sayed using a validated 
enzyme- linked immunosorbent assay method. Analyses of samples collected from 
placebo -treated participants are not pl anned.
Sample retenti on is described in Appendix 1, Section 10.1.12. During this time, samples 
remaining after the bioanalyses may  be used for expl oratory  metabo lism studies or exploratory 
analyses such as bioanalyt ical assay validat ion or cross -validat ion exercises.
8.6. Pharmacodynamics
Samples for assessment of target engagement ( ROand sPD -
1) will  be collected at the times 
specified in the SoA (Secti on
 1.3). Sample retent ion is described in Appendix 1, Section 10.1.12 .
Remaining samples may  be used for addi tional expl oratory  studi es to better unders tand 
LY3462817 and /orthe disease.
8.7. Genetics
A who le blood sample will be co llected for genet ic analysis where local regulat ions allow.
See Secti on10.2, Clinical Laboratory  Tests, and Secti on 1.3, the SoA for sample co llection 
inform ation.  
SeeSecti on 10.5, Genetics for genetic research, custody, and sample retenti on informati on.
8.8. Biomarkers
See the SoA ( Section 1.3) for the frequency  of collecti on of  the bi omarker samples. 
Efficacy -related biomarkers
Certain bio marker swill be co llected to evaluate their association wit h observed clinical 
responses to the study  intervent ion. These bio markers include:
hsCRP, and
ESR
RA characteristics biomarkers
The fo llowing bio marker samples will be co llected to describe the disease characterist ics of the 
rando mized population :
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
54Rheumatoid Factor, and
Anticyclic citrullinated pepti de
Exploratory biomarkers
Serum , plasma, and who le blood RNA and DNA (to enable epigenet ic analyses) samples will be 
collected at the times specified in the SoA ( Secti on1.3) where local regulat ions allow.
Samples may  be used for research on the drug target, disease process, pathways associated with 
disease state, mechanism of act ion of LY3462817, and/or research method or in validat ing 
diagnosti c tool s or assay (s) rel ated to RA.
Sample retenti on is described in Appendix 1, Section 10.1.12.
8.9. Immunogenicity Asse ssments
All samples for immunogenicit y shoul d be taken predose when applicable at the visits and times 
specified in the SoA (Section 1.3)
. Venous blood samples will be collected and evaluated to 
determine antibody  producti on against LY3462817. To interpret the results of immunogenicit y, 
venous blood samples will be collected at the same time po ints to determine the concentrations 
of LY3462817. Ant idrug ant ibodies may be further characterized for their abilit y to neutralize 
the activit y of LY3462817.
Treatment -emergent ant idrug ant ibody (TE-ADA) classificat ionsare described in Sect ion9.4.6 .
Sample retenti on is described in Appendix 1, Section 10.1.12.
8.10. Health Economic s
This sect ion is not appl icable for this study .
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
559. Statistical Considerations
9.1. Statistical Hypotheses
The null hypothesis for the primary  endpoint is that there is no difference between LY3462817 
and placebo in reducing the signs and symptoms of RA as measured by the mean change from 
baseline in DAS28 -CRP at Week 12.
9.2. Sample Size Determination
Approximately  80participants will be randomly  assigned to study  intervent ion. At the 
completion of the study , approximately 40 participants will have been rando mized to 
LY3462817 700 mg and 20 participants will have been randomized to LY 3462817 300 mg and 
placebo during the double -blind treatment .All randomized participants in the modified 
intent-to-treat (m ITT) popul ation will be considered evaluable.
Assuming -1.80 and -0.75 as the DAS28 -CRP change fro m baseline for LY 3462817 700 mg and 
placebo, respectively , with standard deviat ion equal to 1.25, a 2-sided t - testwith =0.05 has 
greater than 80% power to detect a statist ically significant difference in DAS28- CRP change 
from baseline at Week 12. The t -test provi des an approximation to the power calculat ion for the 
primary  analysis ,which will use MMRM as described in Sect ion
 9.4.1 .The comparison of 
LY3462817 300 mg and placebo for the DAS28 -CRP change fro m baseline at Week 12 is 
exploratory ,and therefore, no formal sample size calculat ion was performed for this comparison. 
Com parisons of LY3462817 700 mg and 300mg for the DAS28 -CRP change fro m baseline will 
also be considered exploratory , and again therefore, no formal sample size calculat ion was 
perform ed for this com parison .
9.3. Populations for Analyses
The fo llowing popul ations are defined:
PopulationDescript ion
Modified Intent-to-Treat (mITT)All participants randomly assigned to study intervention and who take at least 
1dose of study intervention. Participants will be analyzed according to the 
interventio n to which they were assigned.
SafetyAll participants randomly assigned to study intervention and who take at least 
1dose of study intervention. Participants will be analyzed according to the 
interventio n they  actually  received within each study period.
Pharmacokinetic (PK) AnalysisAll participants randomly assigned to study intervention and who take at least 1 
dose of study intervention and have PK data available.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
569.4. Statistical Analyses
9.4.1. General Considerations
Statistical analysis o f this study  will be the responsibilit y ofsponsor or its designee. The 
independent variable, previous RA therapy  popul ation, is defined as only csDMARD 
experience dor bDMARD /tsDMARD experience d parti cipants .Unless other wiseindicated in the 
statist ical analysis plan ( SAP), the analyses will be conducted as fo llows:
Analysis for Description
Primary  and secondary endpoint analyses 
comparing LY3462817 to placeboTested at a 2 -sided level of 0.05 for frequentist analyses .
Adjustments for multiplicity None to be performed since this a proof of concept Phase 2 study.
Baseline Defined as the last available value before the first dose of study 
interventio n for both efficacy and safety analyses. In most cases, this 
value will be what is recorded at the randomization visit (Visit 2).
Change f rom baseline Will be calculated as the visit value of interest minus the baseline 
value.
Efficacy and patient -reported outcome 
(PRO )analy sis Analy sis m odels may contain the independent variables such as 
treatment group, baseline disease activity, and previous RA t herapy 
populatio n.
Endpoint analy seswill use the mITT population unless otherwise 
specified .
Dichotomous responder endpoints Missing data will be imputed using the nonresponder imputation (NRI) 
method .
Will be analyzed using a logistic regression model with treatment 
group, baseline disease activity, and previous RA therapy population
as model covariates .
NRI analy sis Participants will be considered nonresponders if :
they do not meet all the clinical response criteria
they are noncompliant with concomitant medication rules 
(Section 6.5)
they permanently  discontinue study intervention at any time 
before the end of the treatment period for any reason, o r
they are randomized and do not have at least 1 postbaseline 
observation.
Continuous efficacy endpoints Mixed -effects model for repeated measures (MMRM) will be used.
The MMRM model will include treatment, strata ( previous RA therapy 
populatio n), baseline value , visit, treatment -by-visit interaction in the 
model as fixed factors ,and patient as a random factor.
An unstructured covariance matrix will be used to model the 
within -subject errors. If this analysis fails to converge, other structures 
will be tested (in this order: Toeplitz, Autoregressive with 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
57Analysis for Description
heterogeneity ,etc.).
The Kenward -Roger approximation will be used to estimate 
denominator degrees of freedom.
Significance tests will be based on least squares means and Type III 
tests.
Participant Disposition A detailed description of participant disposition will be provided, 
including a summary of the number and percentage of participants 
entered into the study and randomized, and number and percentage of 
participants who complete the study or discontinue, both overall and 
by reason for discontinuation. A summary of important protocol 
deviations will be provided.
Participant Characteristics Demographic data are collected and responded to demonstrate that the 
study population represents the target patient population. A summary 
of baseline participant characteristics, historical diagnoses, preexisting 
conditio ns, and prior therapies will be reported by treatment group 
using descriptive stat istics. Other participant characteristics will be 
summarized by treatment group as deemed appropriate.
Concomitant Therapy Previous and concomitant medications will be summarized by 
treatment group and will be presented by Anatomical Therapeutic 
Chemical drug classes using the latest version of the WHO drug 
dictionary.
Treatment Compliance No analy ses are planned to assess treatment compliance, given that 
participants will receive study intervention directly from the 
investigator or designee at the study site, under medical supervision 
(Section 6.4).
Addit ional imputati on methods m ay be considered for all endpoint ty pes.
Estimands for Double -Blind Tr eatment Period
EndpointsEstimand  
strategyEstimand 
descriptionUse post-
discontinuation 
data? ImputationPossible 
analysis 
method 
(estimator)
Primary  
endpoint and 
all other 
continuous 
efficacy and 
PRO 
endpointsHypothetical 
efficacyMean change 
from baseline 
(and mean 
scores) had all 
subjects 
remained on 
randomized
treatment.No, only use 
data up until 
discontinuationParticipants who 
discontinue study 
interventio n have 
remaining data imputed* to 
reflect the expected 
outcome had the s ubject 
remained on the study 
treatment without using 
restricted medications **
(assume missing at random 
[MAR ])MMRM model 
under MAR is 
applied to the 
data prior to 
treatment 
discontinuation
All 
dichotomous 
efficacy and Composite
responderProportio n of 
responders 
where No, only data up 
until 
discontinuation Participants who start 
restricted medicati on**or 
discontinue study Endpoint 
definition 
effectively 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
58EndpointsEstimand  
strategyEstimand 
descriptionUse post-
discontinuation 
data? ImputationPossible 
analysis 
method 
(estimator)
PRO 
endpointsparticipants 
who start 
restricted 
medication or 
discontinue 
study 
interventio n
are considered 
treatment 
failuresis required to 
define endpointinterventio nare defined as 
nonrespondersgives complete 
data
*Note : No actual imputed value per participant , mixed model used to derive result at treatment group level .
** Restricted medications include prohibited medications (Section 6.5.2 ) and permitted medications above the 
allowable dose range (Section 6.5.1).   
Any cha nge to the data analysis methods described in the protocol will require an amendment 
only if the change affects a principal feature of the protocol. Any  other change to the data 
analysis methods described in the protocol, and the just ification for making t he change, will be 
described in the SAP and the clinical study  report (CSR) . Addi tional exploratory  analyses of the 
data will be conducted as deemed appropriate.
The SAP will be finalized prior to unblinding. It will include a more technical and detailed 
descri ption of the statist ical analyses described in this section.
9.4.2. Primary Endpoint (s)
The primary  endpoint is DAS28
-CRP change from baseline at Week 12 .
A restricted maximum likelihood based, MMRM analysis will be used to analyze the primary  
endpo intusing the primary est imand as described in Secti on9.4.1 . 
9.4.3. Secondary Endpoint (s)
Key secondary  efficacy  endpoints include the fo llowing at Week 12 :
Proporti on of  parti cipants achieving :
oACR20
oACR50 , and
oACR70
Change from baseline in :
oTJC
oSJC
oPhGADA_VAS (VAS)
oPaGADA_VAS (VAS)
opatient’s gl obal assessment of arthri tis pain (VAS) , and
opatient’s assessment of physical funct ion (HAQ -DI)
oSF-36
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
59Change from baseline in m eanscore :
oSDAI
oCDAI
Continuous secondary  endpoints will  be analyzed using the model specified for the primary  
analysis described in Section9.4.2 . Dichotomous secondar y endpo ints will be analyzed using the 
logistic regressio n model described in Secti on9.4.2 . 
9.4.4. Exploratory Endpoint (s)
Key explo ratory  efficacy  endpoi nts include the fo llowing :
Proporti on
of parti cipants at Week 12 achieving :
oDAS28 -CRP remissio n defined as DAS28- CRP <2.6 
oDAS28 -CRP LDA defined as DAS28 -CRP ≤3.2
oDAS28 -ESR remissio n defined as DAS28- ESR <2.6 
oDAS28 -ESR LDA defined as DAS28- ESR ≤3.2
oSDAI remissio n defined as SDAI ≤3.3
oSDAI LDA defined as SDAI ≤11
oCDAI remissio n defined as CDAI ≤2.8
oCDAI LDA defined as CDAI ≤10
Change from baseline at Week 12 in the RAMRIS synovit is score from centrally read 
MRI images 
Measures of disease activit y and PRO s at all visits including mean scores, mean change 
from baseline, and proportion of participants achieving desired response
Details o f exploratory  analyses will be described in the SAP that is finalized before database 
lock.
9.4.5. Pharmacokinetic/Pharmacodynamic Analyses
LY3462817 concentrations will be illustrated graphically and summarized descript ively. To 
facilitate the planning of future clinical studies, a model- based approach implemented using 
nonlinear mixed effects modeling (NONMEM) or other appropriate software may be conducted. 
Receptor occupancy  data over time will be summarized by dose level. Exploratory  PK/PD 
analyses may be conducted to evaluate the relat ionship between LY3462817 exposure and 
selected measures o f response (for example, RO, sPD- 1, clinical endpo ints, and/or bi omarkers). 
As appropri ate, data fro m the present study  may be combined wi th data from  other studies in 
model-based analyses. 
Addit ional analyses m ay be conducted if deemed appropriate. Further details on PK and PK/PD 
analyses wi ll be provided in the PK/PD analysis plan.
9.4.6. Evaluation of Immunogenicity
Treatment -emergent antidrug ant ibodies ( ADAs ) are defined as participants
with a 2-fold (1 dilution) increase in t iter than the minimum required dilut ion if no ADAs 
were detected at ba seline (treatment -induced ADA) or 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
60with a 4-fold (2 dilutions) increase in titer compared with baseline if ADAs were detected 
at baseline (treatment -boosted ADA).
The frequency and percentage of participants with preexist ing ADA and who are TE -ADA 
positive(TE-ADA+) to LY3462817 will be tabulated.   
For the TE ADA+ participants, the distribution o f maximum t iters will be described. The 
frequency  of neutralizing ant ibodies, if assessed, may also be tabulated for the TE -ADA+ 
participants.
The rel ationship be tween the presence of ant ibodies and LY3462817 concentrations and PD 
response, including safet y and efficacy , may  also be assessed. Addit ional details may be 
provi ded in the SAP.
9.4.7. Other Safety Analyse s
Analyses/m easures Presented…
Safety analyses: AEs, SAEs, C -SSRS, vital 
signs, ECGs, and laboratory analytesDescriptively summarized by treatment group , will use the safety  
populatio n data
Categorical safety measures Summarized with counts by visit
Continuous safety measures Summarized as mean change by visit
Exposure to study intervention Calculated for each participant and summarized by treatment group 
by treatment period
Adverse events
Adverse events will be coded according to the Medical Dict ionary for Regul atory  Activit ies 
(MedDRA) and summarized by system organ class, preferred term, severit y, and rel ationship to 
the study  intervent ion.All AEs, including pre -existing condit ions, will be listed by participant, 
visit, preferred term, treatment group, severit y, and rel ationship to the treatment.
Treatment -emergent adverse event s
A TEAE i s defined as an event that first occurred or worsened in severit y after baseline, wi th 
baseline defined as all pre -exist ing condit ions recorded at Visit 1 and any AEs recorded before 
the first dose of study  intervent ion (that i s, during the interval between Visit s 1 and 2 and 
recorded with the time of onset before the first dose of study  intervent ion). For events that are 
gender specific, the deno minator and computation of the percentage will include only 
participants from the given gender.
The number and percentage of participants who experienced TEAEs, TEAEs by  maximum  
severit y, deaths, SAEs, TEAEs related to study  intervent ion, discont inuat ions from the treatm ent 
due to an AE, and AESIs will be summarized. Treatment -emergent adverse events (all, by 
maximum severit y), SAEs incl uding deaths, and AEs that lead to treatment discont inuat ion will 
be summarized and analyzed by MedDRA system organ class and preferred term.
Treatment -related TEAEs (TEAEs related to study inter vention) are defined as events that are 
indicated by  the invest igator on the eCRF to be related to treatment.
Adverse events of special interest will be ident ified by a standardized MedDRA query or a 
Lilly -defined MedDRA preferred term list ing.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
61Suicide -related thoughts and behaviors
Suicide-related thoughts and behaviors occurring during treatment will be summarized based on 
responses to the C -SSRS consistent with the C -SSRS Scoring and Data Analysis Guide 
(Columbia Lighthouse Project WWW).
Follow -up emergent adverse events
Follow-up em ergent AEs, SAEs including deaths, and AEs that lead to study  discont inuat ion will 
be summarized.
9.4.8. Other Analyse(s) 
9.4.8.1. Subgroup Analyses
Summaries of subgroups will be provided. Subgroup analyses may be conducted for the pr imary 
endpo int DAS28 -CRP change from baseline using the mITT populat ion.
Subgroups that may be evaluated include
previous RA therapy  popul ation
gender
race
geographi c regi on
previous therapies, and
disease durati on.
Detailed descript ion of the summaries an d/or statistical analyses are provided in the SAP.
9.4.8.2. Supplemental Analyses
Suppl emental  analyses m ay be perform edas deemed necessary .
9.5. Interim Analyses 
Analyses for the primary  database l ock will  be conducted as described in Section 9.4when all 
participants have co mpleted the double -blind treatment period or discont inued treatment.
One interim analysis o f the safet y and efficacy data beplanned prior to database lock, to support 
planning act ivities. This will be done when approximately  40% to 60% of parti cipants have 
completed Peri od 1 (doubl e-blind treatment) or have discont inued treatment. Bayesian posteri or 
probabilit ies will be calculated to assess the efficacy  of LY3462817 700 mg versus placebo for 
DAS28 -CRP for Peri od 1 at the interim analysis. The decisio n rules based upon the posterior 
probabilit y results will help in deciding whether to support further clinical development of 
LY3462817. Addit ionally, this interim ana lysis will aid in the development of PK/PD modeling.
Other interim analyses may be conducted as needed. All interim analyses will be used to support 
planning act ivities associ ated wi th the clinical  devel opment program  and to ai d in the 
development of PK/P D modeling. Since the study  may terminate early  only f or saf ety and/or 
futilit y, no adj ustment of ty pe I error will  be performed. Inform ation about i nterim fut ility and 
decisio n rules will be provi ded in the SAP.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
62Internal assessment committee
Assessment of unblinded interim data will be conducted by  an internal assessment committee 
(AC) with a limited number of prespecified members who do not have direct site con tact or data 
entry  or validati on responsibilit ies (see Section10.1.5 , Appendix 1) . Unblinding details will be 
specified in the unblinding plan sect ion of the SAP or in a separate unblinding document.
Inform ation that m ay unblind the study  during the analyses will not be reported to study  sites or 
blinded study  team  until  the study  has been unblinded. Study  sites will  receive informat ion about 
interim results only  if they need to know for the safet y of their parti cipants.
Evaluat ion of unblinded safet y data by  the internal AC will occur if any o f the following events 
are observed fo llowing review by  the blinded safety  review team :
three or more participants experience TEAEs in the same system organ class , and these 
TEAEs assessed as severe by the invest igator and are judged as related to blinded study 
treatm ent by  the invest igator. 
a malignancy  SAEoccurs during the study .
Pending the evaluat ion by the internal  AC, enrollment and/or further dosing may be stopped.
Unblinding during the interim analyses
Prior to any interim or thefinal database lock, a limited number of preidentified individuals may 
gain access to the unblinded data for internal decisio n making or to init iate the final populat ion 
PK/PD m odel devel opment processes for interim or final analyses. To minimize bias, the SAP 
and PK/PD analysis plan will be finalized and approved before any unblinding. Unblinding 
details will be specified in the SAP or in a separate unblinding document . Inform ation that m ay 
unblind the study  during the analyses will not be reported to study  sites or to the blinded study  
team  until the prespecified milestone for unblinding of study  resul ts. 
9.6. Data Monitoring Committee (DMC)
Not applicable. An internal AC will be used to conduct the interim analysis (Section 9.5).
Overall committee structure information is in Sect ion 10.1.5, Appendix 1 . Details o f the internal 
AC will be provided in the internal AC charter.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
6310. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversi ght 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Counc il for Internati onal Organizat ions of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, Investigator ’sBrochure, and othe r relevant docum ents 
(e.g., adverti sements) m ust be submitted to an IRB/IEC by  the investi gator and revi ewed and 
approved by  the IRB/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or
more frequent ly in accordance wit h the requirements, policies, and procedures 
established by  the IRB/IEC
Notifying the IRB/IEC of SAEs or other significant safet y findings as required by 
IRB/IEC procedures
Provi ding oversight of the conduct of the study  at the site and adherence to 
requi rements of 21 CFR, ICH guidelines, the IRB/IEC, European regulat ion 
536/2014 for clinical studies (if applicable), and all other applicable local 
regul ations
Invest igator sites are compensated for participat ion in the study as detailed in the clinical trial
agreem ent.
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators are 
responsible for providing informat ion on financial interests during the course of the study  and for 
1 year after complet ion of the study .
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
6410.1.3. Informed Consent Proce ss
The invest igator or his/her representative will explain the nature of the study , including the risks 
and benefits, to the parti cipant or his/her legally  authori zed representati ve and answer all
questions regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants or thei r legally  
authori zed representative will be required to sign a statement of informed consent that meets the 
requi rements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portabil ity and 
Accountabilit y Act (HIPAA) requirements, where applicable, and the I RB/IEC or study center.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained before 
the participant was enter ed in the study  and the date the writ ten consent was obtained. The 
authori zed person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be reconsented to the most current version of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi dedto the participant or the participant’s legally  authori zed 
representati veand is kept on file.
When rescreening is performed, the individual must sign a new ICF, repeat all screening 
procedures as described in the SoA (Section 1.3), and will be assigned a new identificat ion 
number (see Section 5.4).
10.1.4. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records ,datasets ,
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information which would make the participant ident ifiable will not be transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data wil l be used by  the 
sponsor in accordance wit h local data protecti on law. The l evel of disclosure m ust also b e 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent .
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
The sponsor has proce sses in place to ensure data protection, informat ion securit y and data 
integrity.These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data securit y breach.
10.1.5. Committees Structure
The internal AC will consist of a limited number of prespecified members not part of the blinded 
study  team  who do not have direct site contact or data entry or validat ion responsibilit ies.Further 
details will be provided in the internal AC charter.   
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
6510.1.6. Dissemination of Clinic al Study Data
A clinical study  report will be provided for this study  and a summary  of study  information 
provi ded on publicly  available websi tes.
10.1.7. Data Quality Assurance
All participant data relat ing to the study  will be recorded on printed or electronic CR F unless 
transmitted to the sponsor or designee electronically (e .g., laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  physically  or electronically 
signing the CRF.
The invest igator must maintain accurate docum entati on (source data) that supports the 
inform ation entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct a ccess to source data documents.
Moni toring details describing strategy  (e.
g., risk -based init iatives in operations and qualit y such 
as Risk Management and Mit igation Strategies and Analyt ical Risk-Based Monitoring), methods, 
responsibilit ies,and requirements, including handling of nonco mpliance issues and monitoring 
techniques are provided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  includin g qualit y 
checking o f the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals (e .
g., Contract 
Research Organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by  authori zed si te personnel  are accurate, com plete, and verifiable fro m source 
docum ents; tha t the safet y and ri ghts of  parti cipants are being protected; and that the study  is 
being conducted in accordance with the current ly approved protocol and any other study 
agreem ents, ICH GCP, and all applicable regu latory requirements.
Records and documents , including signed ICFs, pertaining to the conduct of this study  must be 
retained by the invest igator for the time period outlined in the Clinical Trial Agreement (CTA) 
unless local regulat ions or inst itutional policies requi re a l onger retenti on peri od. N o records may 
be destroy ed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party  without wri tten notificat ion to the sponsor .
In addit ion, sponsor or its representatives will per iodically check a sample of the participant data 
recorded against sour ce documents at the study sit e.The study  may be audi ted by sponsor or its 
representatives, and/or r egulatory agencies at any time. Invest igators will be given notice before 
an audit occ urs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data. The invest igator maintains a separate source for the data entered by  the invest igator or 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
66designee into th e sponsor -provided EDC system. The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ionthat data reported are 
accurate and complete by  signing the CRF .
Addit ionally , electroni c Clinical Outcome Assessment (eCOA) data (participant -focused 
outcom e instrument) will be direct ly recorded by  the participant and invest igator site personnel , 
into an instrument ( for example, tablet ). The eCOA data will serve as the source documentation 
and the invest igator does not maintain a separate written or electronic record of these data.    
Data collected via the sponsor- provided data capture system (s)will bestored at third parties . The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.Prior to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for rete ntion.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention. Data will subsequent ly be transferred fr om the central  vendor to the sponsor data 
warehouse.
Data from co mplaint forms submitted to sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.8. Source Documents
Source documents provide evidence for the existence of the pa rticipant and substantiate the 
integrity of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed fro m source documents 
must be consistent with the source documents o r the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on the 
study . Also, current m edical records must be available.
Definit ion of what constitutes source data can be found in Section10.1.7 .
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will  be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of t he intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
●Failure of the invest igator to comply wit h the protocol, the requirements of the 
IRB/IEC or local healt h authori ties, the sponsor's procedures, or GCP guidelines
●Inadequate recruit ment of parti cipants by  the investi gator
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
67●Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by the applicable 
regul atory  requi rements. The investigator shall p rompt ly inform  the participant and assure s
appropriate participant therapy  and/or foll ow-up.
10.1.10. Publication Policy
In accordance with the sponsor’s publication po licy the results of this study will be submitted for 
publicat ion by a peer -reviewed journal.
10.1.11. Inve stigator Information
Physicians with a specialt yin rheumatology and wit h other specialt iesand experience in 
treatm ent of patients with RA will part icipate as investigators in this clinical trial.
10.1.12. Long -Term Sample Retention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of  the 
intervent ion or after  the intervent ion beco mes commercially  available.
This table describes the reten tion peri od for potential  sample t ypes.
Sample Type CustodianRetention Period
After Last Participant Visit
Pharmacodynamic samples Sponsor or designee up to 7 years
Genetics sample Sponsor or designee up to 7 years
Explo ratory  Biomarker samples Sponsor or designee up to 15 years
Immunogenicity (ADA) sample Sponsor or designee up to 15years
Pharmacokinetic (PK) sample Sponsor or designee up to 1 year
Abbreviations: ADA = antidrug antibody.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
6810.2. Appendix 2: Clinical Laboratory Tests
The tests detailed below will be performed by the central laboratory or by the local laboratory as 
specified in the table .
If the local laboratory  resul ts are used to m ake ei ther a study  interventi on decisi on or response 
evaluat ion, the results must be entered into the CRF.
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed in Sect ion 5
of the protocol.
Addit ional tests m ay be perform ed at any  time during the study  as determined necessary  by the 
investigator or required by  local regulati ons.
Pregnancy testing will be performed according to the SoA (Secti on1.3).
Laboratory  resul ts that coul d unblind the study  will not be reported to invest igative sites 
or other blinded personnel .
Refer to Section 10.6, Appendix 6 for recommended laboratory  testing for hy persensi tivity 
events.
Clinical Laboratory Tests Comments  
Hematology Assay ed by Lilly -designated laboratory
Hemoglobin
Hematocrit
Erythrocy te count (RBCs -Red Blood Cells)
Mean cell volume 
Mean cell hemoglobin
Mean cell hemoglobin concentration
Leukocytes (WBCs -White Blood Cells) 
Differential
   Neutrophils, segmented
   Lymphocy tes
   Monocytes
   Eosinophils
   Basophils
Platelets
Cell Morphology (RBC and WBC)
Clinical Chemistry Assay ed by Lilly -designated laboratory
Sodium
Potassium
Chloride
Bicarbonate
Total bilirubin
Direct bilirubin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
69Clinical Laboratory Tests Comments  
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT)
Blood urea nitrogen (BUN)
Creatinine 
Creatine kinase (CK)
Uric acid
Total protein
Glomerular filtration rate (GFR) Only performed at screening
Albumin
Calcium
Phospho rus
Glucose
Cholesterol
Triglycerides
Urinalysis Assay ed by Lilly -designated laboratory
Specific gravity
pH
Protein
Glucose
Ketones
Bilirubin
Urobilinogen
Blood
Nitrite
Urine leukocyte esterase
Microscopic examination of sediment
Hormones (female)
Serum Pregnancy Assay ed by Lilly -designated laboratory
Urine Pregnancy Evaluated locally
Follicle stimulating hormone (FSH) Assay ed by Lilly -designated laboratory. Optional, performed 
as needed to confirm participant's postmenopausal status.
Serology Assay ed by Lilly -designated laboratory
Tuberculosis (TB) testing See the protocol (Section 8.2.6 ) for more information about TB 
testing.
   QuantiFERON -TB Gold test   Assay ed by Lilly -designated laboratory. Testing can be 
performed by local laboratory if the site prefers.
   T-SPOT or TST Evaluated locally
Human immunodeficiency virus ( HIV) testing Assay ed by Lilly -designated laboratory
Hepatitis C virus (HCV) testing
   HCV antibody Assay ed by Lilly -designated laboratory. Will be confirmed 
with an additional testing method
Hepatitis B virus (HBV) testing Assay ed by Lilly -designated laboratory
   HBV DNA Performed only for participants who test positive for anti -HBc
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
70Clinical Laboratory Tests Comments  
Hepatitis B core antibody (Anti -HBc)
Hepatitis B surface antigen (HBsAg)
Pharmacokinetic Samples
LY3462817 concentration Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites
Flow Cytometry Panel Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites.
T cells, B cells , natural killer cells ( TBNK )
Peripheral helper T cells Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites.
Receptor occupancy Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites.
Biomarkers Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites.
C-reactive protein, high -sensitivity (hsCRP)
Erythrocy te sedimentation rate (ESR)
Soluble programmed cell death ligand –1 
(sPD -L1)
Soluble programmed cell death protein –1 
(sPD -1)
Anti-cyclic citrullinated peptide (anti -CCP)
Rheumatoid factor (RF)
Immunoglobulin Panel Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites.
IgG
IgM
IgA
Cytokine Panel Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites.
Genetics sample Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites.
Stored Sa mples Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites.
Exploratory storage samples: Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites.
Serum
Plasma (EDTA)
Whole blood (EDTA) 
PAXgene (RNA) 
Immunogenicity Samples Assay ed by Lilly -designated laboratory. Results will not be 
provided to the investigative sites.
Anti-LY3462817 antibodies 
Anti-LY3462817 antibodies neutralization
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
7110.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a patient or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE D efinition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments (e .g., ECG, radio logical scans, vital signs measurements), 
including those that worsen fro m baseline, considered clinically significant in the medical 
and scient ific judgment of the invest igator (i .
e., not related to progression of underlying 
disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either a n 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  intervent ion administration even 
though it m ay have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspe cted drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possib le suicidal/self -harming 
intent. Such overdose should be reported regardless of sequelae.
“Lack of efficacy ”or “failure of expected pharmacological act ion”per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy asses sments. 
However, the signs, symptoms, and/or clinical sequelae result ing fro m lack of efficacy 
will be reported as AE or SAE if they fulfill the definit ion of an AE or SAE.
Events NOT Meeting the AE D efinition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments ,which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.
The disease/disorder being studied or expected pr ogressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
72Medical or surgical procedure (e .g., endoscopy , appendectomy): the condit ion that l eads 
to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met (e .g., hospitalizat ion for signs/symptoms of the disease under study , death due to 
progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term  'life-threatening' in the definit ion of 'serious' refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal for 
observat ion and/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complicat ions that occur during hospitalizat ion are AEs. If a 
complicat ion prol ongs hospi talizati on or f ulfills any  other seri ous cri teria, the event i s 
serious. When in doubt as to whether “hospitalizat ion” occurred or was necessary, the AE 
shoul d be considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen fro m 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct norm al 
life funct ions.
This definit ion is not intended to include experiences of relat ively minor med ical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, and 
accidental  traum a (e.g., sprained ankle) which may interfere with or prevent everyday life 
funct ions but do not constitute a substant ial disruptio n.
e.Is a congenit al anomaly/birth defect
f.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting is 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
73appropriate in other situations such as important medical events that may  not be 
immediately  life-threatening or result in de ath or hospitalization but may jeopardize the 
participant or m ay requi re medical or surgi cal intervent ion to prevent 1of the other 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room  or at hom e for allergic bronchospasm, blood dy scrasias or convulsio ns 
that do not result in hospitalizat ion, or development of drug dependency or drug abuse.
10.3.3. Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (e .g., hospital progress notes, laboratory  reports, and di agnosti cs reports) 
related to the event.
The invest igator will then record all relevant AE/SAE informat ion in the CRF.
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to sponsor or designee in lieu of co mpletion of the AE/SAE CRF page.
There m ay be instances when copi es of  medical  records for certain cases are requested by  
sponsor or desi gnee . In thi s case, all participant ident ifiers, wi th the except ion of the 
participant number, will be redacted on the copies of the medical records before 
submissio n to sponsor or des ignee.
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during the 
study  and assi gn it to 1 of the following categories:
Mild: An event that is easily tolerated by the participant, causing minimal disco mfort and 
not interfering wit h every day act ivities.
Moderate: An event that causes sufficient discomfort and interferes wit h norm al everyday 
activit ies.
Severe: An event that prevents normal every day activi ties. An AE that is assessed as 
severe should not be confused wi th a SAE. Severe is a category  utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definit ion of an SAE, NOT when it is rated as severe.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
74Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE.
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relat ionship cannot be rul ed out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, suc h as underlying disease(s), concomitant therapy , and other ri sk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the Invest igator’s Broch ure (IB) and/or Product 
Inform ation, for marketed products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuationsin which an SAE has occurred and the invest igator has minimal 
inform ation to include in the init ial report to sponsor or designee . However, i t is very  
important that the invest igator always make an assessment of causalit y for every  event 
before the init ial transmissio n of the SAE data to sponsor or designee .
The invest igator may change his/her opinio n of causalit y in light of fo llow-up 
inform ation and send a SAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment i s 1of the cr iteria used when determining regulatory reporting 
requi rements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by sponsor or 
designee to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
If a pa rticipant di es during participation in the study  or during a recogni zed f ollow-up 
period,the sponsor or designee will request the investigator to provide a copy  of any 
postm ortem  findings including histopathology .
New or updated informat ion will be record ed in the originally co mpleted CRF.
The invest igator will submit any updated SAE data to sponsor or designee within 
24hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electronic data collect ion tool .
If the electronic system is unavailable, then the site will use the paper SAE data 
collect ion tool  (see next secti on) in order to report the event within 24 hours.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
75The site will enter the SAE da ta into the electronic sy stem  as soon as i t becom es 
available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be 
taken off -line to prevent the entry  of new data or changes to exist ing data.
If a site receives a repor t of a new SAE fro m a study  parti cipant or receives updated data 
on a previously reported SAE after the electronic data collect ion tool  has been taken off -
line, then the site can report this informat ion on a paper SAE form (see next section) or to 
the spon sorby telephone.
Contacts for SAE reporting can be found in site training documents.
SAE Reporting via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
inform ation to the sponsor.
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in site training documents.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
7610.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Women
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming postmenopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e .g., amenorrhea in adoles cents or athl etes) and a m enstrual  cycle cannot be 
confirmed before first dose of study  intervent ion, addi tional eval uation shoul d be considered.
Woman Not of Childbearing Potential
Women in the fo llowing categori es are not considered WOCBP :
1.Prem enarchal
2. P remenopausal  female wi th 1 of the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
For individuals wit h perm anent infert ility due to an alternate medical cause other than the 
above, (e .g., mullerian ag enesis, androgen insensit ivity), invest igator discret ion shoul d be 
applied to determining study  entry .
Note: Documentation can come fro m the site personnel’s review of the participant’s medical 
records, medical examinat ion, or m edical history  interview.
3.Postmenopausal female is defined as, women with:
12 m onths of amenorrhea for women >55, with no need for follicle st imulat ing hormone 
(FSH)
12 m onths of amenorrhea for women >40 y ears old wi th FSH ≥40 m IU/mL and no other 
medical condit ion such as anorexia nervosa and not taking medicat ions during the 
amenorrhea (e.g. oral contraceptives, hormones, gonadotropin releasing hormone, 
antiestrogens, selective estrogen receptor modulators [SERMs ], or chemotherapy  that 
induced amenorrhea )
Participation in the Study
Women of child- bearing potenti al may part icipate in this study.
Women of child- bearing potenti al parti cipat ing must test negative for pregn ancy prior to 
initiation of treatment as indicated by  a negat ive serum  pregnancy test at the screening visit 
followed by a negat ive urine pregnancy  test pri or to exposure. Women of child- bearing potenti al
must test negative for pregnancy prior to administr ation of  the study  drug intervent ion at each 
visit by  a negat ive urine pregnancy test.
Women of child
-bearing potenti al who are abst inent (if this is co mplete abst inence, as their 
preferred and usual lifest yle) or in a same -sex rel ationship (as part of the ir preferred and usual 
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
77lifest yle) must agree to either remain abst inent or stay in a same -sex rel ationship wit hout sexual 
relationships wit h males.
All other WOCBP must agree to use 2forms of effective contraception, where at least 1 form is 
highly  effect ive (less than 1% failure rate), for the ent irety of the study .  
Abstinence or contraception must continue fo llowing com pletion of  study  drug administrati on 
for at least 8weeks or 5 half -lives, whichever is longer.
Acceptable Methods of Contraception
Highly effect ive methods of contraception (less than 1% failure rate) comprise, but are not 
limited to:
combinat ion oral  contraceptives 
implanted con tracepti ves, or 
intrauterine devices. 
Effect ive methods of contraception comprise but are not limited to male or female condo ms with 
spermicide, diaphragms wit h spermic ide,or cervi cal sponges.  
Not Acceptable Methods of Contraception
Use of male and female condoms as a double barrier method is not considered acceptable due to 
the high failure rate when the se barrier methods are combined. 
Barri er protecti on m ethods wi thout concomi tant use of a spermicide are not an effect ive or 
acceptable method of contraception.  
Periodic abst inence (e.g., calendar, ovulat ion, symptothermal, postovulat ion methods), 
declaration of abst inence just for the duration of a trial, and withdrawal are not acceptable 
methods of contraception.
Men
Men, regardless of their fertilit y status, m ust agree to ei ther remain abstinent (if this is their 
preferred and usual lifest yle) or use c ondom s as well as 1additional hi ghly effective (l ess than 
1% failure rate) method of contraception or effect ive method of contraception wit h nonpregnant 
WOCBP partners for the duration of the study  and unt il their study  drug concentrations are 
below the l evel that coul d resul t in a rel evant potenti al exposure to a possible fetus, predicted to 
be5half-lives plus 90 daysfollowing the l ast dose of study  intervent ion.  
Acceptable Methods of Contraception
Highly effect ive methods of contraception (less than 1% failure rate) comprise, but are not 
limited to:
combinat ion oral  contraceptives 
implanted con tracepti ves, or 
intrauterine devices. 
Effect ive methods of contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges.  
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
78Men and their partners may  choose to use a double –barrier m ethod of contraception that must 
include use of a spermicide.
Not Acceptable Methods of Contraception
Use of male and female condoms as a double barrier method is not considered acceptable due to 
the high failure rate when these barrier methods are combined. 
Barri er protecti on m ethods wi thout concomi tant use of a spermicide are not an effect ive or 
acceptable method of contraception.  
Periodic abst inence (e.g., calendar, ovulat ion, symptothermal, po stovul ation methods), 
declaration of abst inence just for the duration of a trial, and withdrawal are not acceptable 
methods of contraception.
Other Guidance
Men should refrain fro m sperm  donat ion for the durati on of  the study  and unt il their study  drug
concentrati ons are bel ow the l evel that coul d resul t in a relevant potenti al exposure to a possible 
fetus , 
predicted to be 5 half -lives plus 90 daysfollowing the last dose of study  intervent ion.
Collection of Pregnancy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s female 
partner who becomes pregnant while the male participant is in this study . This applies only to 
male participants who receive study  intervent ion.
After obtaining the necessary  signed informed consent from the pregnant female partner direct ly, 
the invest igator will record pregnancy informat ion on the appropriate form and submit it to the 
sponsor within 24 hours of learning of the partne r’s pregnancy. The female partner will also be 
followed to determine the outcome of the pregnancy . Information on the status of the mother and 
child will be forwarded to the sponsor. Generally, the fo llow-up will be no l onger than 6 to 
8weeks following th e estimated delivery date. Any terminat ion of the pregnancy will be 
reported including fetal status (presence or absence of ano malies) andindicat ion for the 
procedure. 
Female Participants who become pregnant
The invest igator will co llect pregnancy inform ation on any female participant who becomes 
pregnant whi le part icipating in this study .The init ial informat ion will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning o f a participant's 
pregnancy. 
The parti cipant will be fo llowed to determine the outcome of the pregnancy . The invest igator 
will co llect fo llow-up inform ation on the participant and the neonate and the informat ion will be 
forwarded to the sponsor. Generally, fo llow-up will not be required for longer t han 6 to 8 weeks 
beyo nd the est imated delivery date. Any terminat ion of pregnancy will be reported, including 
fetal status (presence or absence of ano malies) or indicat ion for the procedure.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
79While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  com plicat ion or 
elective termination o f a pregnancy  for medical  reasons will be reported as an AE or SAE. 
A spontaneous abortion (occurring at <2 0weeks gestational age) or still birth (occurring at 
>20weeks gestational age) is always considered to be an SAE and will be reported as such. 
Any poststudy  pregnancy related SAE consi dered reasonably  related to the study  intervent ion by 
the invest igator will be reported to the sponsor as described in Section 8.3.4 . While the 
investigator is not obligated to actively seek this informat ion in former study  parti cipants, he or 
she m ay learn of an SAE throug h spontaneous reporting.
Any female part icipant who becomes pregnant while participat ing in the study  will discont inue 
study  interventi on.If the participant is discont inued fro m the study  intervent ion, the participant 
shoul d remain in the study  if possibl e and co mplete the posttreatment safet y follow-up 
procedures detailed in the SoA (Section 1.3).  
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
8010.5. Appendix 5: Genetics
Use/Analysis of DNA
Genet ic variat ion may impact a participant’s response to study  intervent ion, suscept ibilit y to, and 
severit y and progressi on of  disease. Vari able response to study  intervent ion may be due to 
genet ic determinants that impact drug absorption, distribut ion, metabo lism, and excreti on; 
mechanism o f action of  the drug; di sease et iology; and/or m olecular subt ype of the disease being 
treated. Therefore, where local regulat ions and IRB/IEC allow, a blood sample will be collected 
for DNA analysis fro m consenting part icipants .
DNA samples will be used for research related to LY3462817 or RAand related diseases. They  
may also be used to develop tests/assays including diagnostic tests related to LY3462817 and 
RA. Genet ic research may consist of the analysis of 1or more candi date genes or the analysis of 
genet ic markers throughout the geno me (as appropriate).
DNA samples will be analyzed for genetic variants thought to play a role in RA . Addit ional
analyses may be conducted if it is hypothesized that this may hel p further understand the clinical 
data.
The samples may  be analyzed as part of a mult i-study  assessment of genetic factors involved in 
the response to LY3462817 or study intervent ions of this class to understand study  disease or 
related condi tions.
The res ults of genet ic analyses may be reported in the CSR or in a separate study summary.
The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confident iality.
The samples will be retained while research on LY3462817 or study intervent ions of this class or 
RAcontinues but no longer than 7years or other peri od as per l ocal requi rements.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
8110.6. Appendix 6:  Recommended Laboratory Testing for Hypersensitivity 
Events
Laboratory  assessments should be performed if the participa nt experiences generalized urticaria 
or if anaphylaxis is suspected :
Collect sample after the participant has been stabilized, and within 1 to 2 hours of the 
event; however, samples may be obtained as late as 12 hours after the event as analytes 
can remain altered f or an e xtended peri od of  time. Record the time at which the sample 
was collected.
Obtain a fo llow-up sam ple at the next regularly scheduled visit or after 4 weeks, 
whichever i s later.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
82Hypersensitivity Tests Notes
Selected test may be obtained in the event of anaphylaxis or systemic 
allergic/hypersensitivity reactions.
LY3462817 antidrug antibodies 
(immunogenicity/ADA)Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
LY3462817 concentrations (PK) Assayed by Lill y-designated laboratory. Results will not be provided to the 
investigative sites.
Tryptase Assay ed by Lilly -designated laborato ry. Results will not be provided to the 
investigative sites.
Note: If a tryptase sample is obtained more than 2 hours after the event 
(i.e., within 2 to 12 hours), or is not obtained because more than 12 hours 
have lapsed since the event, obtain urine sample for N-methy lhistamine 
testing. Note that for tryptase serum samples obtained within 2 to 12hours 
of the even t, urine N -methy lhistamine testing is performed in addition to 
tryptase testing. Collect the first void urine following the event. Obtain a 
follow -up urine for N -methy lhistamine testing at the next regularly 
scheduled visit or after 4 weeks, whichever is l ater.
N-methy lhistamine Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Drug -specific IgE Will be performed if a validated assay is available.
Assay ed by Lilly -designated laboratory. Results will not be pr ovided to the 
investigative sites.
Basophil activation test Will be performed if a validated assay is available.
Assay ed by Lilly -designated l aborato ry. Results will not be provided to the 
investigative sites.
NOTE: The basophil activation test is an in vitro cell -based assay that only 
requires a serum sample. It is a surrogate assay for drug -specific IgE but is 
not specific for IgE.
Complement (C3, C3a ,and C5a) Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Cytokine panel Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Abbreviations: ADA = antidrug antibody; IgE = immunoglobulin E; PK = pharmacokinetic.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
8310.7. Appendix 7: Liver Safety: Suggested Actions and Follow -up 
Assessments
Close hepatic monitoring 
This table describes when close hepat ic monitoring shoul d occur.
If a participant with baseline results of... develops the following elevatio ns:
ALT or AST <1.5x ULN ALT or AST ≥3x ULN
ALP <1.5x ULN ALP ≥2x ULN
TBL <1.5x ULN TBL ≥2x ULN (except for participants with Gilbert’s syndrome)
ALT or AST ≥1.5x ULN ALT or AST ≥2x baseline
ALP ≥1.5x ULN ALP ≥2x baseline
TBL ≥1.5x ULN TBL ≥2x baseline (except for participants with Gilbert’s syndrome)
The l aboratory  tests listed under Hepatic Evaluat ion and Testing below, including ALT, AST, 
ALP, TBL, direct bilirubin , gamma- glutamyl  transferase , and creat ine kinase, shoul d be repeated 
within 48 to 72 hours to confirm the abnormalit y and to determine if it is increasing or 
decreasing. 
If the abnormalit y persists or worsens, clinical and laboratory  monitoring, and evaluat ion for 
possible causes of abnormal liver tests should be init iated by  the invest igator in consultat ion with 
the Lilly -designated m edical mo nitor.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , including symptoms, recent illnesses (for example, heart failure, systemic infect ion, 
hypotension, or seizures), recent travel, history  of concomitant medicat ions (including 
over-the-counter), herbal and dietary  supplements, and history  of alcoho l drinking and other 
substance abuse.
Initially, m onitoring of  symptoms and hepat ic biochemica l tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipant’s clinical condit ion and hepat ic biochemical tests. 
Subsequently, the frequency  of monitoring m ay be l owered to once every  1 to 2 weeks, if the 
participant’s clinical co ndition and l ab resul ts stabilize. Moni toring of ALT, AST, ALP, and 
TBL should cont inue unt il levels normalize or return to approximate baseline levels. 
Comprehensive hepatic evaluation
A co mprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
1 or more of these condit ions occur:
If a participant with baseline results of... develops the following elevations:
ALT or AST <1.5x ULN ALT or AST ≥3x ULN with hepatic signs/symptoms*, or ALT or 
AST ≥5x ULN
ALP <1.5x ULN ALP ≥3x ULN 
TBL <1.5x ULN TBL ≥2x ULN (except for participants with Gilbert’s syndrome) 
ALT or AST ≥1.5x ULN ALT or AST ≥2x baseline with hepatic signs/symptoms*, or ALT or 
AST ≥3x baseline 
ALP ≥1.5x ULN ALP ≥2x baseline 
TBL ≥1.5x ULN TBL ≥1.5x baseline (except for participants with Gilbert’s syndrome)
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
84Abbreviations: ALP =alkaline phosphatase; ALT =alanine aminotransferase; AST = aspartate
aminotransferase; TBL =total bilirubin level ; ULN =upper limit of normal.
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, 
and/o r eosinophilia >5%. 
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for prothrombin t ime-internat ional normalized rat io; 
tests for viral hepatit is A, B, C, or E; tests for autoimmune hepat itis; an d an abdominal  imaging 
study  (for example, ul trasound or computed tomography scan).
Based on the participant ’s history  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests fo r hepatit is D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine toxico logy screen, Wilso n’s disease, blood alcohol levels, urinary ethyl glucuronide, and 
serum  phosphat idylethano l.
Based on the circumsta nces and the investigator’s assessment of the participant’s clinical 
condi tion, the invest igator should consider referring the participant for a hepatologist or 
gastroenterologist consultation, magnet ic resonance cho langiopancreatography , endoscopi c 
retrog rade cholangiopancreatography , cardi ac echocardi ogram , or a liver biopsy .
Additional hepatic data collection (hepatic safety CRF)
Addit ional hepatic safet y data collect ion in hepat ic safet y CRF sshoul d be performed in study  
participants who meet 1 or mo re of the fo llowing 5 condi tions: 
If a participant with baseline... has the following elevations…
ALT <1.5 ×ULN ALT ≥5 × ULN on 2 or more consecutive blood tests 
ALP <1.5 × ULN ALP ≥2 × ULN on 2 or more consecutive blood tests
TBL <1.5 × ULN TBL ≥2 × ULN, except for cases of known Gilbert’s syndrome
ALT ≥1.5 × ULN ALT ≥3 × baseline on 2 or more consecutive blood tests
ALP ≥1.5 × ULN ALP ≥2 × baseline on 2 or more consecutive blood tests
TBL ≥1.5 × ULN TBL ≥2 × baseline
Abbreviations: ALP =alkaline phosphatase; ALT =alanine aminotransferase; TBL =total bilirubin level ; 
ULN =upper limit of normal.
Note: The interval between the 2 consecutive blood tests should be at least 2 days.
Hepatic Evaluation Testing
The Lilly -designated central laboratory  must com plete the analysis of all selected testing except 
for microbi ology testing. 
Local  testing m ay be performed in addit ion to central testing when necessary for immediate 
participant m anagement. 
Results will be reported if a validated test or calculation is available.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
85Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
    Neutrophils, segmented Gamma -glutamyl transferase (GGT)
    Lymphocytes Creatine kinase (CK)
    Monocytes Other Chemistry
    Basophils Acetaminophen
    Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
CoagulationCopper
Ethyl alcohol (EtOH)
Prothrombin time, internatio nal no rmalized ratio
(PT-INR)Haptoglobin
SerologyImmunoglobulin A (IgA ; quantitative)
Hepatitis A virus (HAV) testing: Immunoglobulin G (IgG ; quantitative)
    HAV total antibody Immunoglobulin M (IgM ; quantitative)
    HAV IgM antibody Phosphatidylethanol (PEth)
Hepatitis B virus (HBV) testing: Urine Chemistry
    Hepatitis B surface antigen (HBsAg) Drug screen
    Hepatitis B surface antibody (anti -HBs) Ethyl glucuronide (EtG)
    Hepatitis B core total antibody (anti -HBc) Other Serology
    Hepatitis B core IgM antibody Antinuclear antibody (ANA)
    Hepatitis B core IgG antibody Antismooth muscle antibody (ASMA) a
    HBV DNA d Anti- actin antibody b
Hepatitis C virus (HCV) testing: Epstein -Barr virus (EBV) testing:
    HCV antibody     EBV antibody
    HCV RNA d     EBV DNA d
Hepatitis D virus (HDV) testing: Cytomegalovirus (CMV) testing:
    HDV antibody     CMV antibody
Hepatitis E virus (HEV) testing:     CMV DNA d
    HEV IgG antibody Herpes simplex virus (HSV) testing:
    HEV IgM antibody     HSV (Type 1 and 2) antibody 
    HEV RNA d     HSV (Type 1 and 2) DNA d
Microbiology c Liver kidney microsomal type 1 (LKM -1) antibody
Culture:
    Blood
    Urine
aNot required if antiactin antibody is tested.
bNot required if antismooth muscle antibody (ASMA) is tested.
cAssay ed ONLY by investigato r-designated local laboratory; no central testing available.
dReflex/confirmation dependent on regulatory requirements, testing availability, or both.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
8610.8. Appendix 8: Provisions for Changes in Study Conduct During 
Exceptional Circumstances
In rare, exceptional circumstances, barriers may occur that prevent complet ion of mandatory  
visits at study  sites.
When allowed by  local regulati ons, rem ote visi ts perform ed by  trained si te personnel ,including
teleheal th (telephone or technology -assisted vir tual) visits or visits at locations other than the site 
(e.g. participant’s ho me)perform ed by  a mobile healthcare service provider , or al ternate m ethods 
of study  intervent ion delivery  and administration may be considered as alternat ives to replace 
on-sitevisits after consultation and written approval fro m the sponsor.
Once w ritten approval  isgranted for changes in study  conduct, addi tional written gui dance will  
be provided by  the sponsor.
The changes in study conduct captured in this Appendix will not be considered protocol 
deviat ions.Missing data will be captured as protocol deviation(s). Such changes are intended to 
mitigate risks of participants missing visit s, allow participants to continue safely in the study , and 
maintain the data integrit y of the study . Good Clinical Practice compliance and minimization of 
risk to study  integrity are important considerations. Ensuring the safety  of study  parti cipants i s 
the prevailing considerat ion.
The changes to procedures described in this appendix are tempora ry measures intended to be 
used only during specific time periods as directed by the sponsor. Changes in study conduct not 
described in this appendix, or not consistent with applicable local regulat ions, are not allowed.
Informed Consent and Ethical Review Boards
Addit ional written consent fro m the parti cipant will be obtained for those who participate in 
mobilehealth services ,and a method of study  intervent ion administration other than on -site 
visits. The site should also document the participant’s verbal  consent for having telehealt h visits 
and alternate study  intervent ion delivery prior to implementation of these act ivities.
Ethical  review boards and regulatory bodies will be notified as soon as possible to communicate 
implementation of changes in study  conduct due to except ionalcircumstances. To protect the 
safet y of study  participants, urgent changes may  be im plemented before such communications 
are made, but all changes will be reported as soon as possible fo llowing implementation.
Study Interve ntion Administration
In cases when a participant is unable to come to thesite to receive study  intervent ion during 
norm al on-site visi t, the si te shoul d work wi th the sponsor to determine appropriate actions to 
administer the study  interventi on to the par ticipant. Thi s may  include administrati on of  study  
intervent ion to the parti cipant during a mobilehealth visit, provided these requirements are met 
priorto administration of intervent ion:
1.sponsor approves the alternative method to on -site administration, taking local regulatory  
requi rements into considerat ion
2.participant consent must include provisio n of any  personal  informat ion
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
873.delivery  of intervent ion does not compro mise treatment blinding and ensures product 
integrity. The exist ing protocol requirement s for product accountabilit y remain 
unchanged 
4.investigator/sponsor provide soversight of the transport process to ensure accountabilit y 
and product qualit y (i.e., storage condi tions and intact packaging upon receipt)
5.only authori zed study  staff or desi gnee may supply or administer study  intervent ion, and
6.resuscitat ion equipment, emergency drugs, and appropriately trained medical staff must 
be available during the infusio n and for at least 1 hour after the complet ion of the 
infusio n, in case of hy persensi tivity or infusio n site reacti ons.
Concomitant medicat ions may be recorded during a remote visit.
Study Assessments and Procedures
Remotevisitsto com plete appropri ate assessments are acceptable. Site staff shoul d capture the 
visit locat ion and me thod wi th a specific explanat ion for any possible data missing in the source 
docum ent and eCRF.
Visit Windows
Every effort shoul d be made for the participant to return to on -site visi ts as soon as reasonably  
possible, while ensuring the safet y of the parti cipant and investigational site staff. 
Except f or Visi ts 6 and 7, flexibilit y in visit windows can be considered following consultat ion 
with and pri or approval  by the sponsor.
Efficacy Assessments
Conduct or review of participant -reported outcomes may be completed during a telehealt h visit.
These activitiesand h ealth care professio nal RA evaluat ions, including assessments of the 
disease act ivity by a blinded assessor, may  be conducted during a mobilehealt h visit.
Safety Assessments
Adverse events /seriousadverse events , product complaints, and C -SSRS -related assessments 
need to be completed during a telehealt h visit.These activit ies and p hysical examinat ions may be 
completed during a mobilehealt h visit.
Requi rements rel ated to the reporting of SAEs rema in unchanged. 
Sample Collect ion
In exceptional circumstances, to ensure participant safet y and wi th the sponsor’s pri or wri tten 
approval , local laboratory  testing m ay be conducted in lieu of central laboratory  testing only  if it 
is determined that central laboratory  testi ng cannot be conducted. The l ocal laboratory  must also 
be qualified in accordance with applicable local regulat ions. Clinically significant laboratory  
findings must be recorded as an AEin the AE CRF.
Documentation of Changes to S tudy Conduct
Sites m ust identify  and docum ent the details o f how all part icipants, visits ,methods, and 
activit ies conducted were affected by except ional circumstances. 
Consent to be obtained and docum ented as above.  
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
88Source document(s) that are generated at the participant’s home or any  remote locati onshoul d be 
part of the invest igator’s source documentation and should be transferred to the site in a secure 
and timely manner. 
Missing Data and Other Protocol Deviations
Sites shoul d capture specific explanati ons f or any  missing data and other protocol deviat ions in 
source documents ,eCRF s, and other data capture systems .While protocol deviat ions may be 
unavo idable in an except ional circumstance, documentation of deviat ions and missing data will 
be important for data analysis and reporting.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
8910.9. Appendix 9: Abbreviations
Term Definition
AC assessment committee
ACR American College of Rheumatology
ACR20 20% improvement in American College of Rheumatology criteria
ACR50 50% improvement in American College of Rheumatology criteria
ACR70 70% improvement in American College of Rheumatology criteria
ADA antidrug antibody
AE adverse event
AESI adverse event of special interest
AIDS acquired immune deficiency syndrome
ALT alanine aminotransferase
ALP alkaline phosphatase
anti- HBc hepatitis B core antibody
AST aspartate aminotransferase
BCG Bacillus Calmette -Guerin
bDM ARD biologic disease -modifying antirheumatic drug
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the participant is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the participant are not.
A dou ble-blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the subjects 
are aware of the treatment received.
CBD cannabidiol
C-CASA Columbia Classificat ion Algorithm of Suicide Assessment
CDAI Clinical Disease Activity Index
CDC United States Centers for Disease Control and Prevention
CIOMS Council forInternational Organizations ofMedical Sciences
Com panion diagnostic An in vitro diagnostic device (assay  or test) that provides information that is essential 
for the safe and effective use of a corresponding therapeutic product
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
90complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality , purity , durability , reliability , safety  or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, GCP, and applicable regulatory requirements.
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
CRP C-reactive protein
csDMARD conventional synthetic disease -modifying antirheumatic drug
CSR clinical study report
C-SSRS Columbia -Suicide Severity Rating Scale
CTA Clinical Trial Agreement
CXR chest x -ray
DAS28 -CRP Disease Activity Score - C-reactive protein
DAS28 -ESR Disease Activity Score -erythrocy te sedimentatio n rate
DAS28 -hsCRP Disease Activity Score -high sensitivity C-reactive protein
Device Deficiencies Equivalent to product complaint
DMARD disease -modifying antirheumatic drug
DMC data monitoring committee
ECG electrocardiogram
eCOA electronic Clinical Outcome Assessment
eCRF electronic case report form
EDC electronic data capture system
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ESR erythrocy te sedimentation rate
EULAR European League Against Rheumatism
FDA Food and Drug Administration
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
91FSH follicle stimulating hormone
GCP Good Clinical Practice
Gd-DTPA gadolinium diethylenetriamine penta -acetic acid
HAQ -DI Health Assessment Questionnaire -Disability Index
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HIPAA Health Insurance Portability and Accountability Act
HIV human immunodeficiency virus
hsCRP high sensitivity C-reactive protein
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committees
Ig immunoglobulin
IGRA interferon gamma release assay
IL interleukin
IMP Investigational Medicinal Product
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to part icipate. Informed consent is 
documented by means of a written, signed and dated informed consent form .
INR internatio nal no rmalized ratio
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used o r 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRB Institutio nal Review Boards
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
92IV intravenous
IWRS interactive web -response sy stem
LDA low disease activity
LTBI latent tuberculosis infection
MAR missing at random
MedDRA Medical Dictionary for Regulatory Activities
Medical monitor Individual responsible for the medical conduct of the study. Responsibilities of the 
medical monitor may be performed by a clinical research physician, clinical research 
scientist, global safety physician, or other medical officer designated by the sponsor .
mITT modified intent -to-treat
MMRM mixed-effects model for repeated measures
MRI magnetic resonanc eimaging
MTX methotrexate
NIMP Noninvestigational Medicinal Product
NONMEM nonline ar mixed effects modeling
NRI nonresponder imputation
NSAID nonsteroidal anti -inflammatory drug
OMERACT Outcome Measures in Rheumatoid Arthritis Clinical Trials
PaGADA_VAS Patient’s Global Assessment of Disease Activity
participant Equivalent to Clinical Data Interchange Standards Consortium ( CDISC )term “subject”: 
an individual who participates in a clinical trial, either as recipient of an investigational 
medicinal product or as a control .
PCR polymerase chain reaction
PD-1 programmed cell death protein 1
PD-L1 programmed cell death ligand 1
PhGADA_VAS Physician’s Global Assessment of Disease Activity
PK/PD pharmacokinetics/pharmacodynamics
PPD purified protein derivative
PR pulse rate
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
93PRO patient -reported outcomes
Q4W once ever y 4weeks
RA rheumatoid arthritis
RAM RIS Rheumatoid Arthritis Magnetic Resonance Imaging Scoring system
RO receptor occupancy
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SDAI Simplified Disease Activity Index
SERM selective estrogen receptor modulators
SF-36 Medical Outcomes Study 36 -Item Short Form Health Survey
SJC Swollen Joint Counts
SoA Schedule of Activities
sPD-1 soluble programmed cell death protein 1
TB tuberculosis
TBL total bilirubin level
TE-ADA treatment -emergent antidrug antibody
TE-ADA+ treatment -emergent antidrug antibody positive
TEAE treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
TJC Tender Joint Counts
TNF-α tumor necrosis factor -α
tsDMARD targeted synthetic disease -modifying antirheumatic drug
TST tuberculin skin test
ULN upper limit of normal
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
94VAS visual analog scale
WHO World Health Organization
WOCBP woman of childbearing potential
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
9510.10. Appendix 10:  Country Specific Requirements  
Discontinuation of Inadvertently Enrolled Patients in the United Kingdom 
If the sponsor or invest igator ident ifies a participant who did not meet enrollment criteria and 
was inadvertently enrolled, then the participant should be discontinued from study  treatm ent and 
safet y follow up shoul d be perform ed as outlined in Section 1.3(Schedule of Act ivities), 
Secti on8.3(Adverse Events and Serious Adverse Events), and Section 8.2(Safet y Assessments) 
of the protocol.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
9611. References
Aletaha D, Neogi T, Silman AJ, et al. 2010 r heumatoid arthritis classificat ion criteria: an 
American Co llege of Rheumatology/European League Against Rheumat ism co llaborative 
initiative. Arthritis Rheum . 2010;62(9):2569 -2581. https://doi.org/ 10.1002/art.27584
Aletaha D, SmolenJ. The Simplified Disease Act ivity Index (SDAI) and the Clinical Disease 
Activity Index (CDAI): a review of their usefulness and validit y in rheumatoid arthritis. Clin 
Exp Rheumatol . 2005;23(5 suppl 39):S100 -S108.
Aviña -Zubieta JA, Cho i HK, Sadatsafavi M, e t al. Risk of cardi ovascular m ortali ty in patients 
with rheumatoi d arthri tis: a m eta-analysis of observat ional studi es. Arthritis Rheum . 
2008;59(12):1690 -1697. https://doi.org/ 10.1002/art.24092
Aviña -Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of inci dent cardi ovascular events in 
patients wi th rheumatoi d arthri tis: a m eta-analysis of observational studies. Ann Rheum Dis . 
2012;71(9):1524 -1529. https://doi.org/ 10.1136/annrheumdis -2011-200726
Brazi er JE, Harper R, Jones NM, et al. Validat ing the SF -36 hea lth survey quest ionnaire: new 
outcom e measure for primary  care. BMJ . 1992;305(6846):160
-164.
https://doi .org/ 10.1136/bmj.305.6846.160
Bommarito D, Hall C, Taams LS, Corrigall VM. Inflammatory  cytokines com promise 
programmed cell death -1 (PD -1)-mediated T c ell suppressio n in inflammatory  arthri tis through 
up-regulation of so luble PD -1. Clin Exp Immunol. 2017;188(3):455 - 466.
https://doi .org/ 10.1111/cei.12949
Chen X, DuBoi s DC, Almo n RR, Jusko WJ. Biodistribut ion of etanercept to tissues and sites of 
inflammat ion in arthritic rats. Drug Metab Dispos . 2015;43 (6):898-907.
https://doi .org/ 10.1124/dmd.114.062901
Choi HK, Rho YH, Zhu Y, et al. The risk of pulmo nary embolism and deep vein thrombosis in 
rheumatoi d arthri tis: a UK population -based outpatient co hort study. Ann Rheum Dis. 
2013;72(7):1182 -1187. https://doi.org/ 10.1136/annrheumdis -2012-201669
Doran MF, Crowson CS, Pond GR, et al. Frequency o f infection in pat ients with rheumatoi d 
arthri tis compared with controls: a populat ion
-based study . Arthritis Rheum . 
2002;46(9):2287 -2293. https://doi.org/ 10.1002/art.10524
[FDA ]. Gui dance for industry : suicidal  ideati on and behavi or: prospective assessment of 
occurrence in clinical trials. Published August 6, 2012. Accessed July 31, 2020. 
https://www.fda.gov/media/79482/download
Felson DT, Smo len JS, Wells G, et al. American College of Rheumatology /European League 
Against Rheumatism provisio nal definit ion of remissio n in rheumatoid arthrit is for clinical 
trials. Ann Rheum Dis . 2011;70(3):404 -413. https://doi.org/ 10.1136/ard.2011.149765
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthrit is. 
Arthritis Rheum . 1980;23(2):137 -145. https://doi.org/ 10.1002/art.1780230202
Fries JF, Spitz PW, Y oung DY. The dimensio ns of healt h outcomes: the healt h assessment 
questionnaire, disabilit y and pain scales. J Rheumatol . 1982;9(5):789 -793.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
97Fukasawa T, Yoshizaki A, Ebata S, et al. Contributi on of  soluble forms of programmed death 1 
and programmed death l igand 2 to di sease severit y and progression in systemic sclerosis. 
Arthritis Rheumatol . 2017;69(9):1879 -1890. https://doi.org/ 10.1002/art.40164
Gulati N, Suárez -Fariñas M, Correa da Rosa J, Krueger JG. Psoriasis is characterized by 
deficient negat ive immun e regul ation compared to transient delayed -type hypersensit ivity 
reacti ons. F1000Res . 2015;4:149. https://doi .org/ 10.12688/f1000research.6581.1
Guo Y, Walsh AM, Canavan M, et al. Immune checkpoint inhibitor PD -1 pathway is down -
regul ated in syno vium at var ious stages of rheumatoid arthritis disease progression. PLoS One.
2018;13(2):e0192704. https://doi.org/ 10.1371/journal.pone.0192704
Kim SC, Schneeweiss S, Liu J, Solo mon DH. Risk of venous thromboembo lism in pat ients with 
rheumatoi d arthri tis. Arthritis C are Res (Hoboken). 2013;65(10):1600 -1607. 
https://doi .org/ 10.1002/acr.22039
Klarlund M, Østergaard M, Jensen KE, et al. Magnet ic resonance imaging, radiography, and 
scint igraphy of the finger jo ints: one year follow up of pat ients with early  arthri tis. the TIRA 
Group. Ann Rheum Dis . 2000;59(7) :521–528. https://doi .org/ 10.1136/ard.59.7.521
Lee JJ, Pope JE. A meta -analysis of the risk o f venous thromboembo lism in inflammatory  
rheumat ic diseases. Arthritis Res Ther. 2014;16(5):435. https://doi.org/ 10.1186/s1 3075 -014-
0435-y
Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two y ears in physical 
funct ion, structural damage, and signs and symptoms amo ng patients with rheumatoid arthrit is 
treated with infliximab and methotrexate. Arthritis Rheu
m.2004;50(4):1051 - 1065.
https://doi .org/ 10.1002/art.20159
McQueen FM, Dalbeth N. Predict ing joint dam age in rheumatoi d arthri tis using MRI scanning. 
Arthritis Res Ther . 2009;11(5):124. https://doi.org/ 10.1186/ar2778
Mutru O, Laakso M, Isomäki H, Koota K. Ten y ear m ortali ty and causes of death in pat ients 
with rheumatoi d arthri tis. Br Med J (Clin Res Ed.) . 1985;290(6484):1797-1799.
https://doi .org/ 10.1136/bmj.290.6484.1797
Picerno V, Ferro F, Adino lfi A, et al . One year in review: the pathogenesis o f rheumatoi d 
arthri tis. Clin Exp Rheumatol . 2015;33(4):551 -558. https://doi.org/ 10.1093/eurheartj/ehx145
Ogdi e A, Kay McGill N K, Shin DB, et al. Risk of venous thromboembolism in patients with 
psori atic arthrit is, psoriasis and rheumatoid arthritis: a general populat ion-based cohort study . 
Eur Heart J. 2018;39(39):3608 -3614. https://doi.org/ 10.1093/eurheartj/ehx145
Østergaard M, Peterfy  CG, Bi rd P, et al. The OMERACT rheumatoi d 
arthritis magnet ic 
resonance imaging (MRI) scoring system : updated recommendations by the OMERACT MRI 
in Arthri tis Working Group. J Rheumatol . 2017;44(11):1706
-1712.
https://doi .org/ 10.3899/jrheum.161433
Ramey  DR, Fri es JF, Singh G. The Health Assessment Ques tionnaire 1995: status and review. 
In: Spi ker B, edi tor. Quality of Life and Pharmacoeconomics in Clinical Trials 2nd ed . 
Lippincott -Raven; 1996:p 227 -238.
CONFIDENTIAL Protocol  num ber J1A -MC-KDAD(b)
98Rao DA, Gurish MF, Marshall JL, et al. Pathol ogically expanded peripheral T helper cell subset 
drives B cells in rheumatoid arthrit is. Nature. 2017;542(7639):110-114.
https://doi .org/ 10.1038/nature20810
Sihvonen S, Korpela M, Laippala P, et al. Death rates and causes of death in pat ients with
rheumatoi d arthri tis: a popul ation-based study . Scand J Rheumatol . 2004;33(4):221 -227.
https://doi .org/ 10.1080/03009740410005845
Simon TA, Thompson A, Gandhi KK, et al. Incidence o f malignancy in adult pat ients with 
rheumatoi d arthri tis: a m eta-analysis. Arthritis Res Ther . 2015;17(1) :212.
https://doi .org/ 10.1186/s13075-015-0728-9
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American Co llege of Rheumatology guideline for 
the treatment of rheumatoid arthrit is. Arthritis Rheumatol . 2016;68(1):1 -26.
https:// doi.org/ 10.1002/art.39480
Smolen JS, Breedveld FC, Eberl G, et al. Validit y and reliabilit y of the twenty -eight -joint count 
for the assessment of rheumatoid arthritis activit y. Arthritis Rheum. 1995;38(1):38 -43.
https://doi .org/ 10.1002/art.1780380106
Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendat ions for the m anagement 
of rheumatoi d arthri tis wi th synt hetic and bio logical  disease -modifying antirheumat ic drugs: 
2019 update . Ann Rheum Dis .2020;79(6):685 -699. https://doi.org/ 10.1136/annrhe umdis -2019-
216655
Trabattoni D, Saresella M, Pacei M, et al. Costimulatory  pathways in mult iple sclerosi s: 
distinctive expressio n of PD -
1 and PD- L1 in pat ients with different patterns of disease. J 
Immunol. 2009;183(8):4984 -4993. https://doi.org/ 10.4049/ji mmuno l.0901038
Vander Cruyssen B, Van Looy  S, Wyns B, et al. DAS28 best reflects the physician’s clinical 
judgment of response to infliximab therapy in rheumatoid arthritis patients: validat ion of the 
DAS28 score in pat ients under infliximab treatment. Arthritis Res Ther . 2005;7(5):R1063-
R1071. https://doi.org/ 10.1186/ar1787
Wan B, Nie H, Liu A, et al. Aberrant regul ation of  synovial T cell act ivation by so luble 
costim ulatory  molecules in rheumatoi d arthri tis. J Immunol. 2006;177(12):8844 -8850.
https://doi .org/ 10.4049/jimmuno l.177.12.8844
Ware JE Jr, Sherbourne CD. The MOS 36- item short -form health survey  (SF-36). I. conceptual 
framework and item select ion. Med Care . 1992;30(6):473 -483.
Wint hrop KL, Novosad SA, Baddley JW, et al. Opportunist ic infect ions and bio logic therapies in 
immune -mediated inflammatory  diseases: consensus recommendat ions for infecti on reporting 
during clinical trials and postmarket ing surveillance. Ann Rheum Dis . 2015;74 (12):2107 –2116.
https://doi .org/ 10.1136/annrheumdis -
2015-207841
Zhang H, Watanabe R, Berry  GJ, et al. Immuno inhibitory checkpo int deficiency  in medium  and 
large vessel vasculit is. Proc Natl Acad Sci USA. 2017;114(6):E970
-E979.
https://doi .org/ 10.1073/pnas.1616848114
L e o  D o c u m e n t  I D  =  0 3 3 f 1 0 6 6 - c 4 6 1 - 4 1 b 4 - a 3 d 7 - b 8 b 0 4 5 0 6 3 e 6 b 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 0 - D e c - 2 0 2 0  1 4 : 5 3 : 3 0  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 1 - D e c - 2 0 2 0  0 1 : 3 8 : 4 5  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 